

# FINAL PROGRAMME



**35<sup>th</sup> European Meeting on Hypertension  
and Cardiovascular Protection**

**ESH** Gdańsk  
**2026**

INNOVATIONS  
IN CARDIOMETABOLIC MANAGEMENT

**MAY 28-31, 2026 — Gdańsk Amber Expo**





## COMMITTEES

### **ESH 2026 PRESIDENTS**

Krzysztof Narkiewicz – Congress Chair

Andrzej Januszewicz – Co-Chair

### **ESH SCIENTIFIC COUNCIL:**

Thomas Weber (President)

Guido Grassi (Immediate Past President)

Christian Delles (Secretary)

Jan Danser (Treasurer)

Diana Ferrão (Young Investigator Representative)

Michalis Doumas (Coordinator Excellence Centres)

Lene Halvorsen

Atul Pathak (Editor, ESH Clinical Update & News)

Alexandre Persu (Coordinator Working Groups)

Enrique Rodilla Sala

Jana Brguljan (Coordinator Summer Schools)

Mattias Brunström (Ex. Officer for Evidence Synthesis in Clinical Research)

Rosa de Pinho (Coordinator GP Network)

Reinhold Kreutz (Ex. Officer for Conference Planning)

Giuseppe Mancia (Chair, Educational Committee)

Konstantinos Tsioufis (Ex. Officer for International Relations & Research Collaborations)

Michel Burnier (Treasurer ESH Foundation)

Zoltan Jarai (Representative of Presidents of ESH Affiliated / Associated Societies)

### **COUNCIL OF THE POLISH SOCIETY OF HYPERTENSION:**

Mieczysław Litwin (President)

Jacek Wolf (Immediate Past President)

Jacek Lewandowski (President Elect)

Beata Begier-Kraśnińska

Piotr Dobrowolski

Adrian Doroszko

Grzegorz Dzida

Alina Kuryłowicz

Arkadiusz Niklas

Łukasz Obrycki

Aleksander Prejbisz

Łukasz Stryczyński

Anna Szyndler

Andrzej Tykarski

Wiktoria Wojciechowska

Edyta Zbroch



## GENERAL INFORMATION

### REGISTRATION OPENING HOURS

May 27	14.30 – 18.00
May 28	08.00 – 19.30
May 29	07.30 – 19.00
May 30	07.30 – 19.00
May 31	08.00 – 14.30

### EXHIBITION OPENING HOURS

May 28	09.00 – 17.45
May 29	09.00 – 19.00
May 30	09.00 – 19.00
May 31	09.30 – 14.30

### CLOAKROOM OPENING HOURS

May 28	08.00 – 23.00
May 29	07.30 – 19.00
May 30	07.30 – 19.00
May 31	08.00 – 14.30

### ADMISSION

Badge is required for all congress activities.  
Lost badges can be replaced for a fee with proof of registration.  
No children allowed in congress areas.

### LANGUAGE

The official language of the Meeting is English.  
Simultaneous translation into Polish will be provided for all sessions in the Blue and Red meeting rooms.

### SCIENTIFIC PROGRAMME

The Scientific Programme will be available exclusively in a digital format. No printed copies will be provided.  
You can download the programme from the official event website or access it through the **ESH Annual Meetings app**.

### E-POSTER SESSIONS

**May 29** – 17.45 to 19.00

**May 30** – 17.45 to 19.00

E-posters will remain accessible throughout the congress.

### ABSTRACT BOOK

Accepted abstracts will be published in the supplement of the Journal of Hypertension, available on the **ESH Annual Meetings app and on the congress website**.

### NEWS & HIGHLIGHTS

#### ❖ ESH MORNING RUN

**May 29**, 06.30-07.30

*Places are limited and registration is required.*

#### ❖ SUNRISE SESSION

**May 30**, 05.00-06.30

*Places are limited and registration is required.*

#### ❖ YOUNG INVESTIGATORS' QUIZ

**May 30**, 15.00-15.45 Meet the Expert Hub

### LUNCHES

Participants are entitled to a complimentary buffet lunch on May 28, 29, 30 and 31, as part of the registration fee.



## GENERAL INFORMATION

### MEDICAL ASSISTANCE

Participants in need of medical assistance should contact the medical Point located in a dedicate room at the end of Hall B.

### WI-FI

WI-FI will be available in all conference areas.

### CERTIFICATES

Certificates of attendance can be downloaded and emailed from the registration totems at the congress secretariat, on May 31.

### NO-SMOKING

Smoking in the Meeting area is not allowed.

### MOBILE PHONE

Delegates are kindly requested to set their mobile phones on silent mode in the Rooms where scientific sessions are being held.

### TRANSPORTATION

Local transportation during the congress days is kindly offered by the City of Gdańsk.

A dedicated SKM train will run from Gdańsk Główny to AMBEREXPO (no intermediate stops) from 28 to 31 May.

Trams and buses within the public transport network will also be free of charge during the congress days.

**The congress badge will serve as a valid ticket** for the dedicated SKM train as well as for trams and buses within the city network.

### BE CONNECTED!



**Wi-Fi: ESH MEETING 2026**

**PSW: ESHMEETING2026**



**@ESH-European Society of Hypertension**



**@esh\_hypertension**

### ORGANISING AND SCIENTIFIC SECRETARIAT



AIM ITALY – Rome office  
Via Flaminia, 1068  
00189 Rome, Italy  
ph +39-06 330531



# TREAT NON-ADHERENCE AS A RISK FACTOR



**WORLD  
ADHERENCE  
DAY** 27 MARCH



SCAN FOR RESOURCES TO  
HELP KEEP PATIENTS ON TRACK  
**#STAYONTRACK #DONTMISSAMOMENT**

MADE POSSIBLE BY



**ESH** Gdańsk  
2026

**THURSDAY, 28 MAY**





## THURSDAY, MAY 28, 2026

10:00-10:15

BLUE ROOM

### ESH 2026 Welcome Session

#### Welcome address

K. Narkiewicz (Gdańsk, POLAND), A. Januszewicz (Warsaw, POLAND),  
T. Weber (Wels, AUSTRIA)

10:30-11:30

BLUE ROOM

### New Frontiers in Blood Pressure Assessment

Chairpersons: A. Kollias (Athens, GREECE), F. Saladini (Cittadella, ITALY)

10:30-10:38 Update on Nocturnal Blood Pressure  
G. Parati (Milan, ITALY)

10:38-10:40 *Discussion*

10:40-10:48 Update on Blood Pressure Variability  
G. Bilo (Milan, ITALY)

10:48-10:50 *Discussion*

10:50-10:58 Update on Phenotype Heterogeneity  
A. de la Sierra (Terrasa, SPAIN)

10:58-11:00 *Discussion*

11:00-11:08 New Central Blood Pressure Phenotypes  
A. Protogerou (Athens, GREECE)

11:08-11:10 *Discussion*

11:10-11:18 New Cuff – Based Wearables Devices  
G.S. Stergiou (Athens, GREECE)

11:18-11:20 *Discussion*

11:20-11:28 Update on Cuffless Blood Pressure Devices  
A. Schutte (Sydney, AUSTRALIA)

11:28-11:30 *Discussion*

14:45-15:45

BLUE ROOM

### Novel Mechanisms and Therapeutic Targets in CKD

Chairpersons: A. Damianaki (Athens, GREECE),  
L. Vogt (Amsterdam, THE NETHERLANDS)

14:45-14:57 What is new on Aldosterone in CKD?  
G. Wuerzner (Lausanne, SWITZERLAND)

14:57-15:09 Kidney-specific effects of GLP1-Receptor Agonists  
M. Pruijm (Lausanne, SWITZERLAND)

15:09-15:21 Aiming for BP Control vs Albuminuria reduction in cardiorenal  
patients?  
R. Olde Engberink (Amsterdam, THE NETHERLANDS)

15:21-15:33 Migration and CKD risk among migrant populations from  
sub-Saharan Africa  
M.M. Mungamba (Amsterdam, THE NETHERLANDS)

15:33-15:45 *General Discussion*

17:45-19:15

BLUE ROOM

### Opening Ceremony

**HONORARY GUEST:** Lech Wałęsa (*Leader of Solidarity, Former President of Poland,  
Nobel Peace Prize Laureate*)

**LECTURE: *Medicine, science, politics and politicians***  
A. Dominiczak (Glasgow, UNITED KINGDOM)

**HOST:** Grażyna Torbicka

### PRESENTATION OF ESH AWARDS:

Alberto Zanchetti Life Achievement Award  
Björn Folkow Award  
ESH Honorary Membership



## THURSDAY, MAY 28, 2026

10:30-11:30

RED ROOM

### Adherence and Treatment Patterns: Clinical and Lifestyle Perspectives

Chairpersons: P. Gupta (Leicester, UNITED KINGDOM),  
J. Versmissen (Rotterdam, THE NETHERLANDS)

10:30-10:45 Questionnaires for Adherence Testing  
L. Nogueira-Silva (Porto, PORTUGAL)

10:45-11:00 Combined Pill, the Polish Experience  
A. Prejbisz (Warsaw, POLAND)

11:00-11:15 Impact on Blood Pressure and Hormones when living with animals  
C. Borghi (Bologna, ITALY)

11:15-11:30 *General Discussion*

13:15-14:15

RED ROOM

### Managing Blood Pressure in Patients with Dementia: Balancing Risks and Benefits

Chairpersons: A. Benetos (Nancy, FRANCE),  
J.P. Sheppard (Oxford, UNITED KINGDOM)

13:15-13:27 Sarcopenia, Hypertension and Dementia - early signs, diagnosis and prevention  
A. Leibowitz (Ramat Gan, ISRAEL)

13:27-13:39 Hypertension, Syncope and Falls in Older Patients with Dementia  
A. Ungar (Florence, ITALY)

13:39-13:51 Management of Blood Pressure in Older Patients with Dementia:  
the role of Arterial Stiffness  
A. Protogerou (Athens, GREECE)

13:51-14:03 Tailoring Antihypertensive Strategies in Patients with Neurocognitive  
Disorders: From Guidelines to Clinical Practice  
G. Bahat (Istanbul, TURKEY)

14:03-14:15 *General Discussion*



## THURSDAY, MAY 28, 2026

14:45-15:45

RED ROOM

### Endocrine Hypertension: From Guidelines to Individualized Management

Chairpersons: L. Amar (Paris, FRANCE), S. Monticone (Turin, ITALY)

14:45-14:57 Primary Aldosteronism Guidelines: When Can We Skip the Suppression Test?  
P. Mulatero (Turin, ITALY)

14:57-15:09 Surgery in Mild Autonomous Cortisol Secretion: Is It Worth It?  
L. Amar (Paris, FRANCE)

15:09-15:21 Secondary Aldosteronism and Hypertension: Mechanisms and Clinical Implications  
J. Deinum (Nijmegen, THE NETHERLANDS)

15:21-15:33 Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors: Competitors or Allies in Primary Aldosteronism?  
S. Monticone (Turin, ITALY)

15:33-15:45 *General Discussion*

16:15-17:15

RED ROOM

### SESSION OF THE YOUNG INVESTIGATORS GROUP

#### Hypertension in 2036

Chairpersons: C. Antza (Thessaloniki, GREECE), K. Kyriakoulis (Athens, GREECE), Y.Z. Sener (Gaziantep, TURKEY), P. Sinigoj (Ljubljana, SLOVENIA)

16:15-16:24 Hypertension Care in 2035: The Future of the Doctor-Patient Consultation  
D. Ferrão (Porto, PORTUGAL)

16:24-16:33 Digital Twins in Hypertension and Cardiometabolic Care: From Drug Development to Risk Prediction and Precision Individualized Management  
A. Belancic (Rijeka, CROATIA)

16:33-16:42 Measured by Machines? Wearables, Artificial Intelligence and the Future of Hypertension Diagnosis  
E.M. Horváth (Budapest, HUNGARY)

16:42-16:51 Redefining Hypertension Therapy in 2035: Precision, Permanence, and Prevention  
J. Motiejunaite (Paris, FRANCE)

16:51-17:06 Predictions for the Future: Successes and Disappointments  
G. Mancia (Milan, ITALY)

17:06-17:11 *General Discussion*

17:11-17:15 **Adamed Young Investigator Award Ceremony**



## THURSDAY, MAY 28, 2026

10:30-11:30

YELLOW ROOM

### Childhood Hypertension and Adult Target Organ Damage: Breaking the Link

Chairpersons: D. Drozd (Kraków, POLAND), E. Lurbe (Valencia, SPAIN)

10:30-10:42 From Childhood to Adulthood: Treating Obesity to Prevent Hypertension  
D. Drozd (Kraków, POLAND)

10:42-10:54 Vascular Changes of Childhood Hypertension  
M. Litwin (Warsaw, POLAND)

10:54-11:06 Cardiac TOD of Childhood Hypertension  
S. Stabouli (Thessaloniki, GREECE)

11:06-11:18 Renal Consequences of Childhood Hypertension  
T. Seeman (Prague, CZECH REPUBLIC)

11:18-11:30 *General Discussion*

12:00-12:30

YELLOW ROOM

Assembly of the ESH Working Groups

12:30-13:00

YELLOW ROOM

Assembly of the Excellence Centres

13:15-14:15

YELLOW ROOM

### SYMPOSIUM SUPPORTED by **SKY LABS INC.**

#### Cuffless Blood Pressure Monitoring: from validation to real clinical practice

Chairpersons: K.-I. Kim (Seongnam, SOUTH KOREA),  
G.S. Stergiou (Athens, GREECE)

13:15-13:20 Opening Remarks  
G.S. Stergiou (Athens, GREECE),  
K.-I. Kim (Seongnam, SOUTH KOREA)

13:20-13:40 A Ring-type Cuffless BPM: Emerging Innovations to Meet Evolving  
Guideline Standards  
A. Schutte (Sydney, AUSTRALIA)

13:40-14:00 Clinical Evidence of CART BP Aligned with ESH Validation Protocols  
H.-Y. Lee (Seoul, SOUTH KOREA)

14:00-14:10 *Discussion and Q&A*

14:10-14:15 Closing Remarks  
G.S. Stergiou (Athens, GREECE),  
K.-I. Kim (Seongnam, SOUTH KOREA)



## THURSDAY, MAY 28, 2026

14:45-15:45

YELLOW ROOM

### Hypertension and Environmental Pollution: Identifying the Most Vulnerable Groups

Chairpersons: G. Bilo (Milan, ITALY), W. Wojciechowska (Kraków, POLAND)

14:45-15:00 Whether and How Environment Contributes to Hypertension in Children and Adolescents  
D. Drozd (Kraków, POLAND)

15:00-15:15 Women, with a Special Focus on Pregnancy  
T. Socrates (Basel, SWITZERLAND)

15:15-15:30 The Elderly - Most Vulnerable Group to Environmental Pollutants  
J.P. Sheppard (Oxford, UNITED KINGDOM)

15:30-15:45 Summary  
M. Rajzer (Kraków, POLAND)

16:15-17:15

YELLOW ROOM

### Team - Based Hypertension Management in the Primary Care Setting - Joint Session with the Polish Society of Family Medicine (PTMR)

Chairpersons: R. de Pinho (São João da Madeira, PORTUGAL),  
A. Mastalerz-Migas (Wrocław, POLAND)

16:15-16:30 Health Care Professionals' Partnership in Hypertension Management  
E. Rodilla Sala (Valencia, SPAIN)

16:30-16:45 Time needed to treat in Hypertension Care: results of the survey of our Working Group  
J. Nemcsik (Budapest, HUNGARY)

16:45-17:00 Sustainability of Hypertension Management in Primary Care  
M. Pikkemaat (Malmö, SWEDEN)

17:00-17:15 *General Discussion*

10:30-11:30

PURPLE ROOM

### From Fat to Pressure: Decoding the Obesity-Hypertension Link

Chairpersons: V. Kotsis (Thessaloniki, GREECE), J. Jordan (Cologne, GERMANY)

10:30-10:42 Metabolic Memory and Early Life Programming: The Fetal Origins of Hypertension and Obesity  
A. Jelakovic (Zagreb, CROATIA)

10:42-10:54 The Emerging Role of the Gut-Microbiome-Kidney Axis in Obesity-Related Hypertension  
D.N. Mueller (Berlin, GERMANY)

10:54-11:06 The Silent Storm: Subclinical Inflammation and Cardiovascular Risk in Obesity and Hypertension  
P. Anyfanti (Thessaloniki, GREECE)

11:06-11:18 Obesity and Heart Failure: a how-to-manage guide from the EASO and the ESH Working Group on Diabetes and Metabolic Risk Factors  
C. Antza (Thessaloniki, GREECE)

11:18-11:30 *General Discussion*



## THURSDAY, MAY 28, 2026

### 13:15-14:15 PURPLE ROOM

#### Renal Denervation: Expanding Horizons in Hypertension Management

Chairpersons: F. Mahfoud (Basel, SWITZERLAND), J. Weil (Lübeck, GERMANY)

13:15-13:27 Renal Denervation for Heart Failure  
F. Mahfoud (Basel, SWITZERLAND)

13:27-13:39 Renal Denervation in Advanced Chronic Kidney Disease  
A. Bosch (Erlangen, GERMANY)

13:39-13:51 Renal Denervation as a First Line Therapy in Young Patients  
R.M. Bruno (Paris, FRANCE)

13:51-14:03 The Next Step: Multiorgan Denervation?  
M. Schlaich (Perth, AUSTRALIA)

14:03-14:15 *General Discussion*

### 14:45-15:45 PURPLE ROOM

#### Microvascular Ageing in Hypertension: From Mechanisms to Organ Damage

Chairpersons: M. Doumas (Thessaloniki, GREECE), A. Viridis (Pisa, ITALY)

14:45-14:57 Pathophysiology of Microvascular Ageing and Endothelial  
Dysfunction  
A. Mengozzi (Pisa, ITALY)

14:57-15:09 Potential Treatment of Microvascular Ageing  
C. De Ciuceis (Brescia, ITALY)

15:09-15:21 Microvascular Ageing and Sexual Dysfunction in Cardiometabolic  
Disease  
A. Pittaras (Athens, GREECE)

15:21-15:33 PDE-5 Inhibitors as a Vascular Drug in Cardiometabolic Disease  
K. Stavropoulos (Thessaloniki, GREECE)

15:33-15:45 *General Discussion*

### 16:15-17:15 PURPLE ROOM

#### Women and Blood Pressure: Lifelong Challenges and Opportunities

Chairpersons: R. Cifková (Prague, CZECH REPUBLIC),  
M. Perez (Buenos Aires, ARGENTINA)

16:15-16:23 Hypertension Across a Woman's Lifespan  
J. Brguljan Hitij (Ljubljana, SLOVENIA)

16:23-16:25 *Discussion*

16:25-16:33 Hypertensive Disorders of Pregnancy Guidelines and  
Consensus Papers  
T. Socrates (Basel, SWITZERLAND)

16:33-16:35 *Discussion*

16:35-16:43 The Impact of Lifestyle Interventions during Pregnancy on  
Future Metabolic Risk  
K. Stolarz-Skrzypek (Kraków, POLAND)

16:43-16:45 *Discussion*

16:45-16:53 Obesity in Women: Innovative Strategies During Pregnancy to  
Prevent Cardiometabolic Complications  
M. Perez (Buenos Aires, ARGENTINA)

16:53-16:55 *Discussion*

16:55-17:03 P-SCAD in the Postpartum Period  
T. De Backer (Gent, BELGIUM)

17:03-17:05 *Discussion*

17:05-17:13 Models of Care after Hypertensive Disorders of Pregnancy:  
Postpartum Interventions to reduce Long - Term Risk of  
Cardiorenal Disease  
B. Pfaller-Eiwegger (Vienna, AUSTRIA)

17:13-17:15 *Discussion*



## THURSDAY, MAY 28, 2026

10:30-11:30

GREEN ROOM

### Innovations in Large Artery Function and Structure: From Mechanisms to Cardiometabolic Management

Chairpersons: E. Bianchini (Pisa, ITALY), D. Terentes Printzios (Athens, GREECE)

10:30-10:42 Arterial Stiffness and Vascular Ageing: Novel Approaches in Clinical  
Research  
S. Badhwar (Paris, FRANCE)

10:42-10:54 Targeting Endothelial Dysfunction: Innovative Therapies for Arterial  
Health in Cardiometabolic Disease  
A. Triantafyllou (Thessaloniki, GREECE)

10:54-11:06 AI and Digital Health in Large Artery Assessment: From Research to  
Clinical Application  
D. Terentes-Printzios (Athens, GREECE)

11:06-11:18 Reversing Vascular Remodeling: Translating Basic Science into  
Clinical Strategies  
J. Nemcsik (Budapest, HUNGARY)

11:18-11:30 *General Discussion*

13:15-14:15

GREEN ROOM

### Cardiac Damage in CKM Syndrome: Mechanisms and Prevention

Chairpersons: M. Camafort (Barcelona, SPAIN), K. Tsioufis (Athens, GREECE)

13:15-13:25 Unraveling the Mechanisms of Cardiac Damage in CKM Syndrome  
N. De Biase (Pisa, ITALY)

13:25-13:35 How to Characterize the Cardiac Phenotype in Patients with CKM  
Syndrome  
A. Kasiakogias (Athens, GREECE)

13:35-13:45 Time for Change: Can Lifestyle Interventions Prevent the Evolution  
of Cardiac Damage in Patients with CKM Syndrome?  
P. Iliakis (Athens, GREECE)

13:45-13:55 New Therapies in the Prevention of Cardiac Damage in Patients  
with CKM Syndrome  
J.-O. Jeong (Daejeon, SOUTH KOREA)

13:55-14:15 *Discussion*  
*Discussants: P. Iliakis (Athens, GREECE),  
M. Camafort (Barcelona, SPAIN), K. Tsioufis (Athens, GREECE)*



## THURSDAY, MAY 28, 2026

14:45-15:45

GREEN ROOM

### Managing Hypertension and Cardiovascular Risk in Low - Resource Settings

Chairpersons: G. Parati (Milan, ITALY),  
B.-J. van den Born (Amsterdam, THE NETHERLANDS)

14:45-14:57 Implementing the PREVENT Risk Equation in the 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

A. Schutte (Sydney, AUSTRALIA)

14:57-15:09 Low - Dose Combinations With 3 or 4 Blood Pressure-Lowering Medications for the Treatment of Hypertension

D. Ojji (Gwagwalada, Abuja, NIGERIA)

15:09-15:21 Age-Related Blood Pressure Gradients Are Associated with Blood Pressure Control and Global Population Outcomes

M. Schlaich (Perth, AUSTRALIA)

15:21-15:33 Current Clinical Practices and Barriers for Guideline Implementation in High vs Low Resource Settings: an Online Survey

B.-J. van den Born (Amsterdam, THE NETHERLANDS)

15:33-15:45 *General Discussion*

16:15-17:15

GREEN ROOM

### Advances in Understanding and Preventing Cardiometabolic Cerebrovascular Disease

Chairpersons: A. Coca (Barcelona, SPAIN), D. Hering (Gdańsk, POLAND)

16:15-16:30 Residual or Underestimated Risks. Should We Wait for a Stroke?  
T. Yaneva-Sirakova (Sofia, BULGARIA)

16:30-16:45 Cardiometabolic Pathway for Neuro- and Cerebrovascular Protection: A Multifaceted Role of GLP -1 Receptor Agonists  
D. Hering (Gdańsk, POLAND)

16:45-17:00 Innovations in Imaging Biomarkers for Hypertensive Brain Damage  
D. Gasecki (Gdańsk, POLAND)

17:00-17:15 *General Discussion*

For Healthcare Professionals Only

# NOT ALL HYPERTENSION IS THE SAME ALDOSTERONE MAY BE TO BLAME<sup>1,2</sup>

## BEWARE OF ALDO STERONE

A damaging force behind persistently uncontrolled hypertension<sup>1-3\*</sup>



Visit AstraZeneca Medical Booth #5

- In a real-world analysis, ~2 out of 3 patients fail to achieve BP target despite taking 2, 3, or more antihypertensives in the US and UK<sup>4†</sup>
- Aldosterone plays a pivotal role in blood pressure but can be abnormally produced<sup>3,5</sup>
- Excess aldosterone is a key driver of persistently uncontrolled HTN despite standard therapies and increases long-term health risks<sup>1,2,6</sup>

Could targeting aldosterone production offer a potential solution for patients with persistently uncontrolled hypertension?<sup>7,8</sup>

Persistently uncontrolled hypertension describes patients whose blood pressure remains above target despite treatment with at least 2 antihypertensive classes, including those uncontrolled on 2 classes and those with resistant hypertension on 3 or more classes (including a diuretic).<sup>1,9</sup>

\*When produced in excess, aldosterone is a driver of persistently uncontrolled hypertension.<sup>1-3</sup>

†EnligHTN RWE study assessed clinical characteristics and real-world disease burden in >300,000 adults from the US and UK and >175,000 adults from Spain, Germany, and Israel with HTN, diagnosed between 2018 and 2023. Patients were treated with ≥2 antihypertensive medications for ≥30 days and with ≥1 day of follow-up. Analysis used secondary de-identified claims and EMR data. While concurrently treated with ≥2 antihypertensive medications for ≥30 days from index date, controlled HTN was defined as first BP measurement below target and inadequately controlled HTN was defined as first BP measurement above BP target. US BP target: 130/80 mmHg; UK, Spain, Germany, and Israel BP target: <140/90 mmHg. Approximately 2 out of 3 patients with HTN on ≥2 antihypertensive treatments in the US and UK had inadequately controlled BP; 35%–53% of patients with HTN on ≥2 antihypertensive treatments across Spain, Germany, and Israel had inadequately controlled BP.

References: 1. Jones DW et al. J Am Coll Cardiol. 2025;86(18):1567-1678. 2. Brown MJ et al. Ann Intern Med. 2020;173(1):10-20. 3. Papadopoulou-Marketou N et al. Hyperaldosteronism. Endotext [internet]. Updated 16 February 2026. Accessed 5 May 2026. 4. EnligHTN Real-World Evidence Program. Published 6 June 2025. Accessed 5 May 2026. [https://dyoqhggq8g9vgo.cloudfront.net/4d4d150a-bf20-4c76-945a-ce2a670c3c99/7b7173c9-3d6f-41ab-a62a-d30ee0413439/7b7173c9-3d6f-41ab-a62a-d30ee0413439\\_source\\_v.html](https://dyoqhggq8g9vgo.cloudfront.net/4d4d150a-bf20-4c76-945a-ce2a670c3c99/7b7173c9-3d6f-41ab-a62a-d30ee0413439/7b7173c9-3d6f-41ab-a62a-d30ee0413439_source_v.html) 5. Crompton M et al. Biomolecules. 2023;13(6):1004. 6. Otsuka H et al. Int J Mol Sci. 2023;24(6):5370. 7. Blazek O et al. Am J Hypertens. 2023;36(2):73-81. 8. Azizi M. N Engl J Med. 2023;388(5):461-463. 9. Global report on hypertension 2025: high stakes - turning evidence into action. Published 2025. Accessed 5 May 2026. <https://www.who.int/publications/i/item/9789240115569>

Learn more at [HTNandAldosterone.com](https://HTNandAldosterone.com)

VPM ID: PL-28551  
Date of preparation: May 2026

AstraZeneca

**ESH** Gdańsk  
2026

**FRIDAY, 29 MAY**





## FRIDAY, MAY 29, 2026

08:00-09:15

BLUE ROOM

### ORAL SESSION

#### Clinical studies

Chairpersons: B.-J. van den Born (Amsterdam, THE NETHERLANDS),  
M. Tomaszewski (Manchester, UNITED KINGDOM)

08:00-08:09 TRIPLE ANTIHYPERTENSIVE SINGLE-PILL COMBINATIONS INCLUDED AS A WHO ESSENTIAL MEDICINE: CRITICAL REVIEW OF EFFICACY, SAFETY, COST, AND POLICY IMPLICATIONS

G. Satheesh<sup>(1)</sup>, A. Salam<sup>(1)</sup>, R. Dhurjati<sup>(1)</sup>, A. Murphy<sup>(2)</sup>, P. Perel<sup>(2)</sup>, P.K. Whelton<sup>(3)</sup>, T.A. Gaziano<sup>(4)</sup>, D. Prabhakaran<sup>(4)</sup>, D. Ojji<sup>(4)</sup>, H.A.D. Silva<sup>(5)</sup>, S.R. Choudhury<sup>(4)</sup>, J. Cai<sup>(4)</sup>, E. Ogola<sup>(6)</sup>, N.A.B. Ntusi<sup>(7)</sup>, A.G.M. Echeverri<sup>(4)</sup>, M.D. Huffman<sup>(8)</sup>, A.E. Schutte<sup>(8)</sup>, A.E. Moran<sup>(9)</sup>, A. Rodgers<sup>(8)</sup>

<sup>(1)</sup>Hyderabad (INDIA), <sup>(2)</sup>London (UNITED KINGDOM),

<sup>(3)</sup>New Orleans, LA (USA), <sup>(4)</sup>Abuja (NIGERIA), <sup>(5)</sup>

Ragama (SRI LANKA), <sup>(6)</sup>Nairobi (KENYA),

<sup>(7)</sup>Cape Town (SOUTH AFRICA), <sup>(8)</sup>Sydney (AUSTRALIA),

<sup>(9)</sup>New York, NY (USA)

08:09-08:18 FIXED COMBINATION AND MONOTHERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION AT THE STAGE OF PRIMARY CARE IN UKRAINE IN THE CONDITIONS OF A FULL-SCALE MILITARY CONFLICT

O. Rekovets, Y. Sirenko, O.Torbas, G. Primark  
Kyiv (UKRAINE)

08:18-08:27 PATIENT-PROFILED TREATMENT RESPONSES AND CARDIAC ENDPOINT PREVENTION IN THE VALUE OUTCOME TRIAL

P.W. de Leeuw<sup>(1)</sup>, C.L. Søråas<sup>(2)</sup>, K. Jamerson<sup>(3)</sup>, G. Mancia<sup>(4)</sup>, M.H. Mehlum<sup>(2)</sup>, S.E. Kjeldsen<sup>(2)</sup>, M.A. Weber<sup>(5)</sup>

<sup>(1)</sup>Maastricht (THE NETHERLANDS), <sup>(2)</sup>Oslo (NORWAY),

<sup>(3)</sup>Ann Arbor, MI (USA), <sup>(4)</sup>Milan (ITALY), <sup>(5)</sup>New York, NY (USA)

08:27-08:42 **LECTURE**

#### The difficult task of proving aggressive treatment of Hypertension for Kidney Protection

S.E. Kjeldsen (Oslo, NORWAY)

08:42-08:51 IMPACT OF NEBIVOLOL PRESCRIPTION AT DISCHARGE ON LONG-TERM OUTCOMES IN STEMI PATIENTS WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION TREATED WITH DRUG-ELUTING STENTS

S.U. Lee<sup>(1)</sup>, H.W. Kim<sup>(1)</sup>, B.G. Choi<sup>(1)</sup>, M.H. Jeong<sup>(1)</sup>, S.-W. Rha<sup>(2)</sup>

<sup>(1)</sup>Gwangju, <sup>(2)</sup>Seoul (SOUTH KOREA)

08:51-09:00 ADVANCED CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME AND COMBINED MACROVASCULAR AND MICROVASCULAR EVENTS IN DIABETES PATIENTS: RESULTS FROM ADVANCE

S. You<sup>(1)</sup>, R. Wang<sup>(2)</sup>, D. Zheng<sup>(2)</sup>, Q. Li<sup>(2)</sup>, R. Peters<sup>(2)</sup>, X. Chen<sup>(2)</sup>, Y.

Cao<sup>(1)</sup>, C. Anderson<sup>(2)</sup>, M. Woodward<sup>(2)</sup>, J. Chalmers<sup>(2)</sup>, K. Harris<sup>(2)</sup>

<sup>(1)</sup>Suzhou (CHINA), <sup>(2)</sup>Sydney (AUSTRALIA)

09:00-09:09 IMPACT OF UMOD GENOTYPE ON CLINICAL OUTCOMES AMONG PATIENTS WITH HEART FAILURE INITIATING LOOP DIURETICS: A UK BIOBANK PHARMACOGENETIC COHORT STUDY

R. Kreutz, P. Gebert, J. Luo, P. Tassopoulou, J. Bolbrinker, A. Douros  
Berlin (GERMANY)

09:09-09:15 *General Discussion*



## FRIDAY, MAY 29, 2026

09:30-10:30

BLUE ROOM

### Hope, Hype, and Scope of Novel Technologies

Chairpersons: C. Delles (Glasgow, UNITED KINGDOM), D. Ferrão (Porto, PORTUGAL)

- 09:30-09:45 AI in Cardiovascular Medicine - Moving beyond the Hype  
B. Williams (London, UNITED KINGDOM)
- 09:45-10:00 From Influence to Evidence: Who Controls Medicine in the Age of Social Media?  
A. Pathak (Luxembourg, LUXEMBOURG)
- 10:00-10:15 Integrated Polygenic Risk Scores - Are they ready for Clinical Practice?  
O. Melander (Lund, SWEDEN)
- 10:15-10:30 *General Discussion*

11:45-13:00

BLUE ROOM

### Cardiometabolic Innovations Beyond Hypertension - Keynote Lectures

Chairpersons: J. Brguljan Hitij (Ljubljana, SLOVENIA),  
K. Narkiewicz (Gdańsk, POLAND), T. Weber (Wels, AUSTRIA)

- 11:45-12:10 **The GLP-1 innovation story**  
L. Bjerre Knudsen (Copenhagen, DENMARK)
- 12:10-12:35 **Neuroprosthetic innovations for Cardiovascular Instability due to Tetraplegia or Parkinsonism**  
J. Bloch, G. Courtine (Lausanne, SWITZERLAND)
- 12:35-13:00 **BJÖRN FOLKOW AWARD LECTURE**  
**The Sympathetic-Immune Interface: A New Frontier in Hypertension**  
D. Carnevale (Rome/Pozzilli, ITALY)

15:00-16:00

BLUE ROOM

### Novel Tools and Solutions for Improving Hypertension Care *Joint Session with ISH (International Society of Hypertension)*

Chairpersons: A. Januszewicz (Warsaw, POLAND), G.S. Stergiou (Athens, GREECE)

- 15:00-15:04 Introduction  
G.S. Stergiou (Athens, GREECE)
- 15:04-15:16 Patient Education will improve Hypertension Care  
C. Romero (Atlanta, GA, USA)
- 15:16-15:28 Involvement of Pharmacies will improve Hypertension Care  
M.S. Fernandez-Alfonso (Madrid, SPAIN)
- 15:28-15:40 Novel Technology Solutions will improve Hypertension Care  
K. Kario (Shimotsuke, JAPAN)
- 15:40-15:55 *Panel Discussion*
- 15:55-16:00 Summary  
A. Januszewicz (Warsaw, POLAND)



## FRIDAY, MAY 29, 2026

16:15-17:30

BLUE ROOM

### CLINICAL TRIALS

#### Hotline - Session 1

Chairpersons: S.E. Kjeldsen (Oslo, NORWAY), G. Mancina (Milan, ITALY),  
N. Poulter (London, UNITED KINGDOM)

16:15-16:30 ERSHAM Randomized Trial: Effects of Renal Denervation on Stress  
and Anxiety in Hypertension  
F. Tatakis (Athens, GREECE)

16:30-16:35 *Discussion*  
*Discussant: A. Persu (Brussels, BELGIUM)*

16:35-16:50 The OPTIMAL-HT Study: Evaluation of Triple Single-Pill Combination  
Therapy in Achieving Stringent Blood Pressure Targets  
A. Prejbisz (Warsaw, POLAND)

16:50-16:55 *Discussion*  
*Discussant: M. Burnier (Lausanne, SWITZERLAND)*

16:55-17:10 Effect of the Dual Endothelin Receptor Antagonist Aprocitentan on  
Albuminuria  
M. Schlaich (Perth, AUSTRALIA)

17:10-17:15 *Discussion*  
*Discussant: P. Sarafidis (Thessaloniki, GREECE)*

17:15-17:30 Baxdrostat in Hard-to-Control Hypertension: Novel Insights from  
BaxHTN and Bax24 Trials  
B. Williams (London, UNITED KINGDOM)

17:30-17:35 *Discussion*  
*Discussant: T. Guzik (Kraków/Edinburgh, UNITED KINGDOM)*

08:00-09:15

RED ROOM

### CLINICAL CASES - SESSION 1

#### Focus on Secondary Hypertension

Chairpersons: L. Amar (Paris, FRANCE), P. Mulatero (Turin, ITALY),  
A. Persu (Brussels, BELGIUM)

08:00-08:20 Hiding in Plain Sight: The Importance of Reviewing Historical  
Data in PPGL Diagnosis  
M. Zitek (Prague, CZECH REPUBLIC)

08:20-08:40 Primary Aldosteronism - wide spectrum of clinical manifestations  
F. Buffolo (Turin, ITALY)

08:40-09:00 Patient with Hypertension and Neurological Complications  
A. Aniszczyk-Hybiak (Warsaw, POLAND)

09:00-09:15 *General Discussion*



## FRIDAY, MAY 29, 2026

09:30-10:30

RED ROOM

### Hypertension in CKM: Phenotypes in Key Organs

Chairpersons: E. Agabiti Rosei (Brescia, ITALY), L.V. Halvorsen (Oslo, NORWAY)

09:30-09:42 Large arteries  
T. Weber (Wels, AUSTRIA)

09:42-09:54 Small Arteries  
R.M. Bruno (Paris, FRANCE)

09:54-10:06 Heart  
S. Masi (Pisa, ITALY)

10:06-10:18 Kidney  
P. Sarafidis (Athens, GREECE)

10:18-10:30 *General Discussion*

10:45-11:30

RED ROOM

### MINI-SYMPOSIUM SUPPORTED **BY ELI LILLY**

#### Incretin - based therapies - A breakthrough in the treatment of Type 2 Diabetes?

Chairperson: L. Czupryniak (Warsaw, POLAND)

10:45-11:00 Can remission become the primary goal for type 2 diabetes?  
L. Czupryniak (Warsaw, POLAND)

11:00-11:15 Do incretin-based therapies improve cardiovascular prognosis in type 2 diabetes?  
P. Balsam (Warsaw, POLAND)

11:15-11:30 Q&A

11:45-13:00

RED ROOM

### DOCTOR, CAN I...? Practical answers to Real - World Hypertension Dilemmas (part 1) - *Joint Session with the Polish Society of Hypertension*

Chairpersons: R. de Pinho (São João da Madeira, PORTUGAL),  
A. Olszanecka (Kraków, POLAND)

11:45-11:50 Do I have to take these pills for life?  
J. Lewandowski (Warsaw, POLAND)

11:50-11:55 Can you prescribe something to help me sleep?  
K. Grabowski (Gdańsk, POLAND)

11:55-12:00 I sweat a lot - is it my medication or hypertension?  
P. Kubalski (Grudzińdz, POLAND)

12:00-12:05 Can I use a sauna if I'm treated for hypertension?  
M. Pikkemaat (Malmö, SWEDEN)

12:05-12:10 Can I take erectile dysfunction medication with antihypertensives?  
J. Wolf (Gdańsk, POLAND)

12:10-12:15 My BP changes with seasons - should I adjust my medication?  
A. Triantafyllou (Thessaloniki, GREECE)

12:15-12:20 Is my smartwatch accurate for blood pressure measurement?  
J. Lima Nogueira (Ovar, Aveiro, PORTUGAL)

12:20-12:25 My sodium is low - should I eat more salt?  
K. Stolarz-Skrzypek (Kraków, POLAND)

12:25-12:30 I'm going to the mountains - how high can I safely go by cable car?  
G. Bilo (Milan, ITALY)

12:30-12:35 Should I take my medication before or after breakfast?  
A. Kurylowicz (Warsaw, POLAND)

12:35-13:00 *General Discussion*



## FRIDAY, MAY 29, 2026

15:00-16:00

RED ROOM

**Obesity and Hypertension: A new framework for integrated  
Cardiometabolic Care**

*Joint Session with EASO (European Association for the Study of  
Obesity)*

Chairpersons: V. Yumuk (Istanbul, TURKEY), T. Weber (Wels, AUSTRIA)

15:00-15:04 Introduction  
V. Yumuk (Istanbul, TURKEY)

15:04-15:16 The EASO Framework for the Diagnosis, Staging and Treatment of  
Obesity: Considerations for Hypertension  
L. Busetto (Padua, ITALY)

15:16-15:28 The EASO Framework for the Pharmacological Treatment of Obesity  
and Its Complications  
A. Ciudin Mihai (Barcelona, SPAIN)

15:28-15:40 Managing Hypertension in Adults with Obesity: From Clinical  
Trials to Everyday Practice  
K. Narkiewicz (Gdańsk, POLAND)

15:40-15:55 *Panel Discussion*

15:55-16:00 Summary  
T. Weber (Wels, AUSTRIA)

16:15-17:30

RED ROOM

### ORAL SESSION

**Best Original Abstracts**

Chairpersons: C. Delles (Glasgow, UNITED KINGDOM),  
M.L. Muesan (Brescia, ITALY), M. Stathoulopoulou (Athens, GREECE)

16:15-16:25 HYPERTENSIVE RESPONSE TO EXERCISE INDEXED TO OXYGEN  
CONSUMPTION: ASSOCIATIONS WITH CARDIOVASCULAR - RENAL  
FUNCTION AND PROGNOSIS IN PATIENTS WITH ESTABLISHED  
ARTERIAL HYPERTENSION  
N. De Biase<sup>(1)</sup>, S. Moura-Ferreira<sup>(2)</sup>, S. De Schutter<sup>(3)</sup>,  
L. Del Punta<sup>(1)</sup>, A. Gevaert<sup>(3)</sup>, J. Verwerft<sup>(2)</sup>, S. Taddei<sup>(1)</sup>,  
N.R. Pugliese<sup>(1)</sup>, S. Masi<sup>(1)</sup>  
<sup>(1)</sup>Pisa (ITALY), <sup>(2)</sup>Hasselt, <sup>(3)</sup>Antwerp (BELGIUM)

16:25-16:35 MATERNAL SLEEP DISORDERS DRIVE PREECLAMPSIA VIA  
IMMUNOMETABOLIC REPROGRAMMING OF NEUTROPHILS  
J. Zhu, Y. Xiong  
Shanghai (CHINA)

16:35-16:45 PROPORTION OF HOME BLOOD PRESSURE MEASUREMENTS  
OUTSIDE TARGET RANGE IS ASSOCIATED WITH PREECLAMPSIA RISK  
L. Voskamp, S. Raven, A. Franx, A.H.J. Danser, M. Rousian,  
K. Verdonk  
Rotterdam (THE NETHERLANDS)

16:45-16:55 EFFICACY AND SAFETY OF ALDOSTERONE SYNTHASE INHIBITORS FOR  
BLOOD PRESSURE REDUCTION IN PATIENTS WITH CKD: A SYSTEMATIC  
REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS  
M. Theodorakopoulou<sup>(1)</sup>, F. Iatridi<sup>(1)</sup>, A. Georgiou<sup>(1)</sup>,  
A. Karagiannidis<sup>(1)</sup>, M. Hecking<sup>(2)</sup>, P. Sarafidis<sup>(1)</sup>  
<sup>(1)</sup>Thessaloniki (GREECE), <sup>(2)</sup>Vienna (AUSTRIA)

16:55-17:30 *General Discussion*



## FRIDAY, MAY 29, 2026

08:00-09:15

YELLOW ROOM

### ORAL SESSION

#### Device-based Treatment

Chairpersons: D. Hering (Gdańsk, POLAND), J. Weil (Lübeck, GERMANY)

08:00-08:09 SELECTIVE RENAL NERVE NEUROMODULATION PRODUCES ROBUST ANTIHYPERTENSIVE EFFECTS IN OBESITY-INDUCED HYPERTENSION

I. Salman(1), O. Ameer(1), Y.-H. Hsieh(2), S. Lewis(2)

(1) Riyadh (SAUDI ARABIA), (2) Cleveland, OH (USA)

08:09-08:18 THE CLINICAL BENEFIT AFTER RADIOFREQUENCY RENAL DENERVATION: POOLED 36-MONTH RESULTS FROM THE SPYRAL CLINICAL PROGRAM

R. E. Schmieder(1), D. Kandzari(2), R. Whitbourn(3), M. Böhm(4),  
M. Gilbertson(5), F. Mahfoud(6)

(1) Erlangen (GERMANY), (2) Atlanta, GA (USA),

(3) Melbourne (AUSTRALIA), (4) Homburg (GERMANY),

(5) Minneapolis, MN (USA), (6) Basel (SWITZERLAND)

08:18-08:27 THREE-YEAR OUTCOMES OF RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH HYPERTENSION-MEDIATED ORGAN DAMAGE: INSIGHTS FROM THE GLOBAL SYMPPLICITY REGISTRY DEFINE

F. Mahfoud(1), M. Schlaich(2), R. E. Schmieder(3), F. Sharif(4),  
F. Ribichini(5), Y. Korytchenko(6), C. Alfaro Vives(6), M. Böhm(7)

(1) Basel (SWITZERLAND), (2) Perth (AUSTRALIA), (3) Erlangen

(GERMANY), (4) Galway (IRELAND), (5) Verona (ITALY), (6) Santa Rosa,

CA (USA), (7) Homburg (GERMANY)

08:27-08:36 SUSTAINED 5-YEAR BLOOD PRESSURE REDUCTION BY RADIOFREQUENCY RENAL DENERVATION IN UNCONTROLLED HYPERTENSION: THE SWEDISH REGISTRY FOR RENAL DENERVATION

A. Jekell, K. Landstedt, J. Spaak, T. Kahan

Stockholm (SWEDEN)

08:36-08:45 SIGNIFICANT REDUCTIONS IN ALBUMINURIA IN PATIENTS WITH HYPERTENSIVE RENAL DISEASE AFTER RADIOFREQUENCY RENAL DENERVATION; RESULTS FROM THE GLOBAL SYMPPLICITY REGISTRY DEFINE

M. Schlaich(1), M. Böhm(2), F. Mahfoud(3), F. Sharif(4), F. Ribichini(5),  
M.Y. Kim(6), B. Maus(6), R. E. Schmieder(7)

(1) Perth (AUSTRALIA), (2) Homburg (GERMANY), (3) Basel (SWITZERLAND),

(4) Galway (IRELAND), (5) Verona (ITALY), (6) Santa Rosa, CA (USA), (7)

Erlangen (GERMANY)

08:45-09:00 **LECTURE**

#### Hepatic Denervation: A Useful Approach as Multiorgan Intervention?

M. Böhm (Homburg, GERMANY)

09:00-09:09 COST-EFFECTIVENESS OF RENAL DENERVATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

K. Kyriakoulis(1), A. Vakka(1), P. Iliakis(1), F. Tatakis(1), C. Fragkoulis(1),  
K. Papadomarkaki(1), N. Stamataki(1), P. Tsioufis(1), E. Manta(1),

S. Soulaïdopoulos(1), A. Kasiakogias(1), D. Konstantinidis(1),

K. Dimitriadis(1), D. Hettrick(2), R. E. Schmieder(3), K. Tsioufis(1)

(1) Athens (GREECE), (2) Santa Rosa, CA (USA), (3) Erlangen (GERMANY)

09:09-09:15 *General Discussion*



## FRIDAY, MAY 29, 2026

09:30-10:30

YELLOW ROOM

### Aldosterone: Novel Insights from Basic Research

Chairpersons: A.H.J. Danser (Rotterdam, THE NETHERLANDS),  
R. Touyz (Montreal, CANADA)

09:30-09:45 From Low Renin Hypertension to Primary Aldosteronism: The New Genetic Spectrum of Aldosterone Dysregulation  
S. Boulkroun (Paris, FRANCE)

09:45-10:00 Adaptive Autoimmunity in Primary Aldosteronism  
T.M. Seccia (Padua, ITALY)

10:00-10:15 Evolutionary Insights into Aldosterone-Producing Adenomas from Single-Cell and Spatial Biology  
T.A. Williams (Munich, GERMANY)

10:15-10:30 *General Discussion*

10:45-11:30

YELLOW ROOM

### MINI-SYMPOSIUM SUPPORTED **BY SERVIER**

#### Simplify to Amplify: Building the Winning Treatment Plan in Hypertension

Chairpersons: C. Borghi (Bologna, ITALY), G.S. Stergiou (Athens, GREECE)

10:45-10:49 Introduction  
C. Borghi (Bologna, ITALY)

10:49-11:01 Getting the First Step Right in Hypertension  
R. de Pinho (São João da Madeira, PORTUGAL)

11:01-11:13 Triple SPCs: Simplifying Treatment, Strengthening Control  
A. Prejbisz (Warsaw, POLAND)

11:13-11:25 From Guidelines to Adherence-Driven Outcomes: the Value of SPCs  
A. Schutte (Sydney, AUSTRALIA)

11:25-11:30 Discussion and Conclusion  
G.S. Stergiou (Athens, GREECE)

13:45-14:30

YELLOW ROOM

### SYMPOSIUM SUPPORTED **BY SERVIER**

#### Treat-to-Benefit with Quadruple Therapy: The Missing Piece in the Hypertension Puzzle

Chairpersons: K. Narkiewicz (Gdańsk, POLAND), B. Ponte (Geneva, SWITZERLAND)

13:45-13:49 Introduction  
K. Narkiewicz (Gdańsk, POLAND)

13:49-14:01 Mapping Patients that are Difficult-to-Manage: Who are we treating?  
A. Kaplon-Cieslicka (Warsaw, POLAND)

14:01-14:13 Completing the Mechanistic Puzzle of Blood Pressure Regulation  
S. Masi (Pisa, ITALY)

14:13-14:25 When benefit matters most: the impact of One Pill  
A. Pathak (Luxembourg, LUXEMBOURG)

14:25-14:30 Conclusion  
B. Ponte (Geneva, SWITZERLAND)



## FRIDAY, MAY 29, 2026

15:00-16:00

YELLOW ROOM

### The Mysteries of the Microbiome

Chairpersons: K. Kaminski (Białystok, POLAND), F. Limbourg (Hannover, GERMANY)

15:00-15:15 The Microbiome for Dummies: How to do Microbiome Research  
B. Verhaar (Amsterdam, THE NETHERLANDS)

15:15-15:30 Role of the Microbiome in the Gut-Heart-Kidney Crosstalk  
T. Niiranen (Turku, FINLAND)

15:30-15:45 Butyrate Rescues Cardiac Metabolic Dysfunction in Hypertensive  
Heart Failure with Preserved Ejection Fraction  
N. Haase (Berlin, GERMANY)

15:45-16:00 *General Discussion*

16:15-17:30

YELLOW ROOM

### ORAL SESSION

#### Hypertension in Older Adults

Chairpersons: A. Benetos (Nancy, FRANCE), T. Grodzicki (Kraków, POLAND)

16:15-16:30 **LECTURE**  
**Managing Hypertension in Older Adults: Evidence,  
Targets, and Challenges**  
P.K. Whelton (New Orleans, LA, USA)

16:30-16:39 CONTRIBUTIONS OF VASCULAR SMOOTH MUSCLE CELLS TO  
VASCULAR WALL STIFFENING  
Z. Hong  
(Lubbock, TX, USA)

16:39-16:48 SYSTOLIC BLOOD PRESSURE VARIABILITY AND ALL-CAUSE AND  
CAUSE-SPECIFIC MORTALITY: A MULTI-CENTER COHORT STUDY OF  
1.4 MILLION OLDER ADULTS  
Z. Zhou, J. Qi, L. Lin, P. Yin, L. Wang  
Beijing (CHINA)

16:48-16:57 PROGNOSTIC VALUE OF BLOOD PRESSURE PHENOTYPES IN THE  
VERY OLD SUBJECTS  
A. Croce<sup>(1)</sup>, A. Ricco<sup>(1)</sup>, A. Ornago<sup>(2)</sup>, M.C. Ferrara<sup>(1)</sup>, D. Soranna<sup>(1)</sup>,  
A. Zamboni<sup>(1)</sup>, M.F. Pengo<sup>(1)</sup>, G. Bilo<sup>(1,3)</sup>, G. Belleli<sup>(1,3)</sup>, G. Parati<sup>(1)</sup>  
<sup>(1)</sup>Milan (ITALY), <sup>(2)</sup>Stockholm (SWEDEN), <sup>(3)</sup>Monza (ITALY)

16:57-17:06 ANALYSIS OF 24-HOUR AMBULATORY BLOOD PRESSURE DATA  
USING NONLINEAR DYNAMICS IN RELATION TO COGNITIVE  
FUNCTION AND DEMENTIA  
J. Melgarejo<sup>(1)</sup>, S. Mejia-Arango<sup>(1)</sup>, L. Mena<sup>(2)</sup>, J. Lee<sup>(3)</sup>, J. Terwilliger<sup>(3)</sup>,  
J. Banegas<sup>(4)</sup>, G. Maestre<sup>(1)</sup>  
<sup>(1)</sup>Harlingen, TX (USA), <sup>(2)</sup>Mazatlan (MEXICO), <sup>(3)</sup>  
New York, NY (USA), <sup>(4)</sup>Madrid (SPAIN)

17:06-17:15 PREDICTORS OF MORTALITY IN HYPERTENSIVE OLDER PATIENTS  
WITH OBSTRUCTIVE SLEEP APNEA: THE ROLE OF INTERMITTENT  
HYPOXIA  
A. Gezzi, F. Spannella, S. Sarnari, F. Giulietti, M. Landolfo,  
R. Sarzani  
Ancona (ITALY)

17:15-17:24 ADAPTATION OF ANTIHYPERTENSIVE THERAPY AFTER DISCHARGE  
FROM A GERIATRIC UNIT FOLLOWING NON-CARDIOVASCULAR  
HOSPITALIZATION  
M. Sant'Ana, M. Fidalgo, G. Sarmiento, Y. Martins, H. Ribeiro  
Oliveira de Azeméis (PORTUGAL)

17:24-17:30 *General Discussion*



## FRIDAY, MAY 29, 2026

08:00-09:15

PURPLE ROOM

### ORAL SESSION

#### Lifestyle and Obesity

Chairpersons: A.M. Sharma (Berlin, GERMANY), J. Spaak (Stockholm, SWEDEN)

08:00-08:09 EFFECTIVENESS OF A STRUCTURED EXERCISE INTERVENTION TO NORMALIZE BLOOD PRESSURE AND NOCTURNAL DIPPING IN HYPERTENSIVE PATIENTS (END-HT) IN HONG KONG PRIMARY CARE: A RCT  
E.K. Lee<sup>(1)</sup>, S. Wang<sup>(1)</sup>, B. Yip<sup>(1)</sup>, D. Zhang<sup>(1)</sup>, J. Cheng<sup>(1)</sup>, S.S. Hui<sup>(1)</sup>, E.Y.T. Yu<sup>(1)</sup>, M. Leung<sup>(1)</sup>, W.C.W. Chu<sup>(1)</sup>, A.S. Mihailidou<sup>(2)</sup>, S. Wong<sup>(1)</sup>  
<sup>(1)</sup>Hong Kong (HONG KONG SAR, CHINA)<sup>(2)</sup>Sydney, (AUSTRALIA)

08:09-08:18 SALT AWARENESS, INTAKE PERCEPTIONS, AND HYPERTENSION CONTROL: GENDER, AGE AND STATUS DIFFERENCES IN CROATIA - MMM 2023 AND HUNTING THE SILENT KILLER PROGRAM  
V. Bralic Lang<sup>(1)</sup>, A. Soldo<sup>(1)</sup>, O. Velkovski Skopic<sup>(1)</sup>, M. Seljan Zubic<sup>(1)</sup>, I. Pavesic<sup>(1)</sup>, T. Saban<sup>(1)</sup>, M. Marinovic Glavic<sup>(1,2)</sup>, S. VlahTomicevic<sup>(1)</sup>, A. Jelakovic<sup>(1,2)</sup>, I. Pecin<sup>(1)</sup>, M. Domislovic<sup>(1)</sup>, M. Boljesic Dumancic<sup>(1,3)</sup>, P. Susnjara<sup>(1,3)</sup>, J. Josipovic<sup>(1)</sup>, A. Stupin<sup>(1,3)</sup>, L. Bilajac<sup>(1,2)</sup>, K. Grguric<sup>(1)</sup>, B. Jelakovic<sup>(1)</sup>  
<sup>(1)</sup>Zagreb,<sup>(2)</sup>Rijeka,<sup>(3)</sup>Osijek (CROATIA)

08:18-08:27 ABDOMINAL OBESITY IS A MORE IMPORTANT RISK PHENOTYPE FOR CKM SYNDROME THAN GENERAL OBESITY: A CROSS-SECTIONAL NHANES STUDY  
S. Zuo, J. Mu  
 Xi'an (CHINA)

08:27-08:36 ARM AND THIGH TO WAIST CIRCUMFERENCE RATIO (ATC/WC) AND ALL-CAUSE MORTALITY, CARDIOVASCULAR MORTALITY, HYPERTENSION, DIABETES, AND RESTING TACHYCARDIA  
S. Zuo, J. Mu  
 Xi'an (CHINA)

08:36-08:51 **LECTURE**  
**Physical Activity in Cardiometabolic Disease: How little is not enough and how much is too much**  
 T. Yates (Leicester, UNITED KINGDOM)

08:51-09:15 *General Discussion*

10:15-11:00

PURPLE ROOM

### MINI-SYMPOSIUM SUPPORTED **BY EGIS**

#### Uric Acid in the Spotlight: From Risk Marker to Therapeutic Target

Chairpersons: K. Narkiewicz (Gdańsk, POLAND),  
 M. Vrablik (Prague, CZECH REPUBLIC)

10:15-10:20 Introduction  
 K. Narkiewicz (Gdańsk, POLAND)

10:20-10:35 Hyperuricemia is a cardiovascular risk  
 C. Borghi (Bologna, ITALY)

10:35-10:45 Value judgement of patient-centric approaches in hyperuricemia: challenges and solutions  
 Z. Kaló (Budapest, HUNGARY)

10:45-10:55 How to treat hyperuricemia - International Expert Opinion  
 J. Domienik-Karłowicz (Warsaw, POLAND)

10:55-11:00 *Discussion*  
 M. Vrablik (CZECH REPUBLIC)



## FRIDAY, MAY 29, 2026

13:00-13:45

PURPLE ROOM

Assembly of National Societies

15:00-16:00

PURPLE ROOM

**The Early Roots of Cardiovascular Disease: Why Childhood Matters**

Chairpersons: S. Stabouli (Thessaloniki, GREECE), P. Sinigoj (Ljubljana, SLOVENIA)

15:00-15:12 Long-Term Consequences of Elevated Blood Pressure in Childhood  
J. Feber (Ottawa, CANADA)

15:12-15:24 What definitions of Hypertension and Treatment Targets should we use in Pediatrics?  
E. Lurbe (Valencia, SPAIN)

15:24-15:36 Hemodynamics of Childhood Hypertension  
M.D. Sinha (London, UNITED KINGDOM)

15:36-15:48 Primary Hypertension in Childhood and Neuro-Immunometabolic Disease  
M. Litwin (Warsaw, POLAND)

15:48-16:00 *General Discussion*

16:15-17:30

PURPLE ROOM

### ORAL SESSION

**Blood Pressure Phenotypes**

Chairpersons: J. Redon (Valencia, SPAIN), M.P. Schneider (Geneva, SWITZERLAND)

16:15-16:24 ASSOCIATION BETWEEN SHORT-TERM BLOOD PRESSURE VARIABILITY AND ARTERIAL STIFFNESS IN A PREHYPERTENSIVE POPULATION

M. Liu<sup>(1)</sup>, Z. Li<sup>(2)</sup>, T. Wang<sup>(2)</sup>, R. Liu<sup>(1)</sup>, R. Wang<sup>(3)</sup>, Y. Zhang<sup>(4)</sup>, S. Zhang<sup>(5)</sup>, X. Chen<sup>(6)</sup>, H. Liu<sup>(7)</sup>, H. Jia<sup>(1)</sup>, R. Geng<sup>(1)</sup>, J. Li<sup>(1)</sup>, W. Zhang<sup>(1,2)</sup>

<sup>(1)</sup>Zhengzhou, <sup>(2)</sup>Beijing, <sup>(3)</sup>Puyang, <sup>(4)</sup>Fuzhou, <sup>(5)</sup>Daqing, <sup>(6)</sup>Wenzhou, <sup>(8)</sup>Zhoukou (CHINA)

16:24-16:33 PREVALENCE AND CARDIO-KIDNEY-METABOLIC PROFILES ACROSS AHA 2025 BLOOD PRESSURE CATEGORIES IN 32,046 ADULTS WITH TYPE 2 DIABETES IN A HIGH-RISK POPULATION

K. Ahmed, S. Naqvi, O. Ali, M. Ahmed  
Abu Dhabi (UNITED ARAB EMIRATES)

16:33-16:42 INCIDENT HYPERTENSION AFTER LONG COVID: A POPULATION-BASED COHORT STUDY

A. Carlsson<sup>(1)</sup>, P. Lindberg<sup>(1,2)</sup>, S. Lee<sup>(3)</sup>, A. Norrman<sup>(1,4)</sup>, M. Kisiel<sup>(3)</sup>, M. Ståhlberg<sup>(1,2)</sup>, C. Wachtler<sup>(1,4)</sup>, M. Nygren-Bonnier<sup>(1)</sup>, S. Wiqvist<sup>(1)</sup>, A. Fedorowski<sup>(1,2)</sup>

<sup>(1)</sup>Huddinge, <sup>(2)</sup>Solna, <sup>(3)</sup>Uppsala, <sup>(4)</sup>Stockholm (SWEDEN)

16:42-16:57 **LECTURE**

**World Adherence Day - Where we are and how you can help**

P. Gupta (Leicester, UNITED KINGDOM)



## FRIDAY, MAY 29, 2026

16:57-17:06 RISK OF ARTERIAL STIFFNESS ASSOCIATED WITH MASKED HYPERTENSION AND NOCTURNAL DIPPING STATUS MEASURED BY AMBULATORY BLOOD PRESSURE MONITORING IN POPULATION WITH PREHYPERTENSION

Y. Wu<sup>(1)</sup>, Z. Li, Q. Zhao<sup>(1,2)</sup>, H. Jia<sup>(1)</sup>, R. Geng<sup>(1)</sup>, J. Li<sup>(1)</sup>, Q. Zhang<sup>(1)</sup>,  
W. Zhang<sup>(1,2)</sup>

<sup>(1)</sup> Beijing, <sup>(2)</sup> Zhengzhou (CHINA)

17:06-17:15 BLOOD PRESSURE AND CARDIOVASCULAR RISK IN A CONTEMPORARY COHORT OF YOUNG ADULTS OF NORWEGIAN ORIGIN

E. Aaseth, S. Halvorsen, S.E. Kjeldsen, J. Gravning

Oslo (NORWAY)

17:15-17:24 BLOOD PRESSURE CONTROL AMONG PATIENTS WITH CORONARY ARTERY DISEASE: RESULTS FROM THE POLASPIRE III STUDY

M. Burzynska<sup>(1,2)</sup>, K. Chlebus<sup>(3)</sup>, Z. Gasior<sup>(4)</sup>, A. Kubica<sup>(5)</sup>,  
J. Kazmierczak<sup>(6)</sup>, A. Szymanska<sup>(2)</sup>, M. Komar<sup>(7)</sup>, S. Bartus<sup>(7)</sup>,  
P. Wacinski<sup>(8)</sup>, O. Barchuk<sup>(2)</sup>, P. Jankowski<sup>(2)</sup>

<sup>(1)</sup> Łódź, <sup>(2)</sup> Warsaw, <sup>(3)</sup> Gdańsk, <sup>(4)</sup> Katowice, <sup>(5)</sup> Bydgoszcz,

<sup>(6)</sup> Szczecin, <sup>(7)</sup> Kraków, <sup>(8)</sup> Lublin (POLAND)

17:24-17:30 *General Discussion*



## FRIDAY, MAY 29, 2026

08:00-09:15

GREEN ROOM

### ORAL SESSION

#### Drivers of Cardiovascular Risk

Chairpersons: M. Lopez - Sublet (Bobigny, FRANCE) J. Wang (Shanghai, CHINA)

08:00-08:09 DISCORDANT LDL-C AND ESTIMATED LDL-TRIGLYCERIDES IN PREDICTING HYPERTENSION RISK: A PROSPECTIVE ANALYSIS FROM CHARLS

X. Li<sup>(1)</sup>, X. Wu<sup>(1)</sup>, W. Chen<sup>(1)</sup>, H. Shen<sup>(1)</sup>, Y. Jiang<sup>(2)</sup>, C. Ma<sup>(1)</sup>

<sup>(1)</sup>Suzhou, <sup>(2)</sup>Deyang (CHINA)

08:09-08:18 ESTIMATED SMALL DENSE LDL-CHOLESTEROL IS INDEPENDENTLY ASSOCIATED WITH ARTERIAL STIFFNESS: A LARGE JAPANESE SCREENING STUDY

Y. Akasaki, S. Shinchi, D. Tokutake, S. Kawasoe, T. Kubozono, H. Miyahara, K. Tokusige, M. Ohishi  
Kagoshima (JAPAN)

08:18-08:27 TRIGLYCERIDE-GLUCOSE INDEX (TYG) IS INDEPENDENTLY ASSOCIATED WITH BLOOD PRESSURE IN A CROSS-SECTIONAL SAMPLE OF HYPERTENSIVE PATIENTS REFERRED TO A TERTIARY HYPERTENSION CENTER

M.N. Guler, A. Franzin, G.E. Sabbà, A. Giontella, V. Zanconato, F. Stocchetti, S. Grisenti, F. Bertucci, S. Bonafini, C. Fava  
Verona (ITALY)

08:27-08:36 LEVERAGING A GENETIC PROXY TO INVESTIGATE THE EFFECTS OF LIFELONG ADRENERGIC RECEPTOR BLOCKADE

L.-F. Yeo<sup>(1)</sup>, J. Palmu<sup>(1)</sup>, J. Isojärvi<sup>(1)</sup>, T. Hellman<sup>(1)</sup>, T. Niiranen<sup>(1,2)</sup>

<sup>(1)</sup>Turku, <sup>(2)</sup>Helsinki (FINLAND)

08:36-08:45 THE METABOLIC SCORE FOR INSULIN RESISTANCE AS AN EFFECTIVE TOOL FOR CARDIOVASCULAR RISK STRATIFICATION IN KIDNEY TRANSPLANT RECIPIENTS

D. Picciotto, E. Bussalino, S. Cavagnaro, A. Parodi, M.T. Gandolfo, R. Russo, E. Russo, F. Viazzi  
Genoa (ITALY)

08:45-08:54 ASSOCIATION OF COMBINED SYSTOLIC AND DIASTOLIC BLOOD HYPERTENSION WITH CARDIOVASCULAR DISEASE

E. Tantisattamo<sup>(1,2,3,4)</sup>, D. Pleanrungsri<sup>(1,4)</sup>, K. Siwawut<sup>(1,4)</sup>, R. Silprasert<sup>(1)</sup>, T. Wong<sup>(1)</sup>, Y. Ha<sup>(1)</sup>, A. Shah<sup>(1)</sup>, D. Sibichen<sup>(1)</sup>, T. Chalermchat<sup>(1,4)</sup>, N. Mohpichai<sup>(1,4)</sup>, S. Buadee<sup>(1,4)</sup>, T. Asawaroekwisoot<sup>(1)</sup>, N. Paisarntanawat<sup>(1)</sup>, W. Noree<sup>(1)</sup>, K. Chartpattananan<sup>(1)</sup>, P. Ansusinha<sup>(1)</sup>, N. Deepan<sup>(1)</sup>, I. Boonyawannukul<sup>(1,5)</sup>, C. Kookanok<sup>(1,6)</sup>, K. Lee<sup>(1,7)</sup>, N. Kitlertbanchong<sup>(1,4)</sup>

<sup>(1)</sup>Orange, CA, <sup>(2)</sup>Long Beach, CA, <sup>(3)</sup>Royal Oak, MI (USA),

<sup>(4)</sup>Bangkok (THAILANDIA) <sup>(5)</sup>Khon Kaen (THAILAND),

<sup>(6)</sup>Brooklyn, NY(USA), <sup>(7)</sup>Daegu (SOUTH KOREA)

08:54-09:09 **LECTURE**

**Added Value of Novel Risk Factors: A Critical Appraisal**

M. Volpe (Rome, ITALY)

09:09-09:15 *General Discussion*



## FRIDAY, MAY 29, 2026

09:30-10:30

GREEN ROOM

### How to communicate Cardiovascular Risk and Therapy

Chairpersons: J. Vaclavik (Ostrava, CZECH REPUBLIC),  
J. Versmissen (Rotterdam, THE NETHERLANDS)

09:30-09:45 Interactive Clinical Cases  
M. Burnier (Lausanne, SWITZERLAND)

09:45-10:00 Principles of Effective Communication  
D. Lupi (Zagreb, CROATIA)

10:00-10:15 Common Barriers and Pitfalls  
A. Szyndler (Gdańsk, POLAND)

10:15-10:30 Key Skills to Improve Patient Understanding  
V. Cunha (Almada, PORTUGAL)

10:45-11:30

GREEN ROOM

### MINI-SYMPOSIUM SUPPORTED **BY GEDEON RICHTER**

#### Integrated Management of Hypertension, Dyslipidaemia and Vascular Complications

Chairperson: T. Weber (Wels, AUSTRIA)

10:45-10:50 Introduction  
T. Weber (Wels, AUSTRIA)

10:50-11:05 *Thought-provoking introductory presentation*  
Treatment algorithms for hypertensive patients with hyperlipidaemia and diabetes, including management beyond triple combination therapy  
A. Januszewicz (Warsaw, POLAND)

11:05-11:10 Presentation on the main topic  
D. Hering (Gdańsk, POLAND)

11:10-11:30 *Expert Roundtable Discussion*



## FRIDAY, MAY 29, 2026

13:45-14:45

GREEN ROOM

### SYMPOSIUM SUPPORTED **BY MERCK**

#### Individualising Antihypertensive Therapy: The Role of Beta-Blockers Across Cardiovascular and Systemic Comorbidities

Chairpersons: R. Kreutz (Berlin, GERMANY), T. Weber (Wels, AUSTRIA)

13:45-14:05 Beta-Blockers in patients with Hypertension and Cardiovascular Disease: When to Start and When to Continue  
R. Fontes - Carvalho (Porto, PORTUGAL)

14:05-14:25 Beyond the Heart: Benefits of Beta-Blockers in Hypertension and Non - Cardiovascular Comorbidities  
F. Mahfoud (Basel, SWITZERLAND)

14:25-14:45 *Expert Discussion and Clinical Case - Based Debate*

15:00-15:45

GREEN ROOM

### MINI-SYMPOSIUM SUPPORTED **BY MENARINI GROUP**

#### Navigating complexity in hypertension management: from pharmacology to patient profile

Chairpersons: T. Benedek (Tirgu Mures, ROMANIA), R. Kreutz (Berlin, GERMANY)

15:00-15:03 Introduction  
T. Benedek (Tirgu Mures, ROMANIA), R. Kreutz (Berlin, GERMANY)

15:03-15:10 Keeping up the fight against hypertension: the key role of SPCs  
R. Kreutz (Berlin, GERMANY)

15:10-15:20 Not all the SPCs are made the same: the case of nebivolol based SPCs  
M. Volpe (Rome, ITALY)

15:20-15:40 Clinical decision making in hypertension management: matching pharmacology to patient profile  
R. Dechend (Berlin, GERMANY), P. Van de Borne (Brussels, BELGIUM)

15:40-15:45 Conclusions and Q&A  
T. Benedek (Tirgu Mures, ROMANIA), R. Kreutz (Berlin, GERMANY)

16:15-17:30

GREEN ROOM

### ORAL SESSION

#### Hemodynamics and Organ Damage

Chairpersons: T. Kahan (Stockholm, SWEDEN), S. Laurent (Paris, FRANCE)

16:15-16:24 DETERMINANTS AND PROGNOSTIC VALUE OF BLOOD PRESSURE TRAJECTORIES DURING GRADED EXERCISEN.  
N. Cauwenberghs<sup>(1)</sup>, A. Carlen<sup>(2)</sup>, T. Lindow<sup>(3)</sup>, V. ElMBERG<sup>(3)</sup>, L. Brudin<sup>(4)</sup>, M. Ekstrom<sup>(3)</sup>, K. Hedman<sup>(2)</sup>  
<sup>(1)</sup> Leuven, <sup>(2)</sup> Linköping, <sup>(3)</sup> Lund, <sup>(4)</sup> Kalmar (SWEDEN)

16:24-16:33 HIGHER EXERCISE BLOOD PRESSURE IS ASSOCIATED WITH INCREASED URINARY ALBUMIN EXCRETION IN NON-DIABETIC POPULATION WITH NON-ELEVATED BLOOD PRESSURE  
J. Sung, S.J. Cho, W.S. Huh  
Seoul (SOUTH KOREA)

16:33-16:42 REDUCED NOCTURNAL BLOOD PRESSURE DECLINE RATE IS ASSOCIATED WITH CORONARY SLOW FLOW IN HYPERTENSIVE PATIENTS  
X. Di<sup>(1)</sup>, K. Zhang<sup>(2)</sup>, F. Zhang<sup>(1)</sup>, Y. Zhang<sup>(1)</sup>, M. Li<sup>(1)</sup>, Q. Wang<sup>(1)</sup>  
<sup>(1)</sup> Lanzhou, <sup>(2)</sup> Xi'an (CHINA)



## FRIDAY, MAY 29, 2026

16:42-16:51 SUBCLINICAL ECHOCARDIOGRAPHIC RIGHT HEART CHANGES  
ACROSS DIASTOLIC FUNCTION CONTINUUM IN SYSTEMIC ARTERIAL  
HYPERTENSION

M. Pizon, M. Stopa, J. Raczka, M. Rajzer, A. Olszanecka  
Kraków (POLAND)

16:51-17:00 PROLONGED BED REST IS A WATER-LOSING PHENOTYPE ASSOCIATED  
WITH INCREASED BLOOD PRESSURE

X. Peng<sup>(1)</sup>, L. Jesper Philip<sup>(1)</sup>, R. Billette de Villemeur<sup>(2)</sup>, M. Mandic<sup>(3)</sup>,  
R. Fernandez Gonzalo<sup>(3)</sup>, J. Titze (4,5,6), M. Rauh<sup>(7)</sup>, L. Vogt<sup>(1)</sup>,  
R.H.G. Olde Engberink<sup>(1)</sup>

<sup>(1)</sup>Amsterdam (THE NETHERLANDS), <sup>(2)</sup>Toulouse (FRANCE),

<sup>(3)</sup>Stockholm (SWEDEN), <sup>(4)</sup>Durham, NC (USA), <sup>(5)</sup>Singapore  
(SINGAPORE), <sup>(6)</sup>Hamburg (GERMANY), <sup>(7)</sup>Erlangen (GERMANY)

17:00-17:15 **LECTURE**

**The Pickering–Platt Debate Revisited: Is Hypertension One  
Disease or Many?**

P.W. De Leeuw (Maastricht, THE NETHERLANDS)

17:15-17:30 *General Discussion*

08:30-10:00

ORANGE ROOM

**HANDS-ON WORKSHOP**

**Renal Ultrasound in Primary and Secondary Hypertension (Basics)**

Chairpersons: A. Januszewicz (Warsaw, POLAND), A. Persu (Brussels, BELGIUM)

08:30-08:40 Technical basics of ultrasound; normal anatomic  
findings and common abnormalities of the renal and  
urogenital tract (renal masses, nephrolithiasis,  
hydronephrosis)  
M. Januszewicz (Warsaw, POLAND)

08:40-08:50 Renal duplex ultrasound: atherosclerotic renal artery  
stenosis and fibromuscular dysplasia/renal resistive index  
B. Ponte (Geneva, SWITZERLAND)

08:50-09:00 VEXUS as a tool to assess fluid status in the hypertensive  
patient  
M. Pruijm (Lausanne, SWITZERLAND)

09:00-10:00 Practical kidney examination by experts and supervised  
hands-on kidney ultrasound with healthy volunteers  
D. Ackermann (Bern, SWITZERLAND), M. Januszewicz  
(Warsaw, POLAND), B. Ponte (Geneva, SWITZERLAND),  
M. Pruijm (Lausanne, SWITZERLAND)



## FRIDAY, MAY 29, 2026

10:45-11:30

ORANGE ROOM

### MINI-SYMPOSIUM SUPPORTED **BY AN EDUCATIONAL GRANT FROM SANOFI**

Tailoring Therapy for Hypertension: Case-Based Insights Implementing  
Single-Pill Combinations for Improved Hypertension Outcomes

Chairpersons: R. Kreutz (Berlin, GERMANY), J. Brguljan Hitij (Ljubljana, SLOVENIA)

10:45-10:48 Introduction  
R. Kreutz (Berlin, GERMANY)

10:48-11:03 Case 1: Tailoring Therapy for Hypertension: CAD  
P. Van de Borne (Brussels, BELGIUM)

11:03-11:18 Case 2: Tailoring Therapy for Hypertension: Diabetes with CKD  
M. Burnier (Lausanne, SWITZERLAND)

11:18-11:28 Q&A

11:28-11:30 Conclusion  
J. Brguljan Hitij (Ljubljana, SLOVENIA)

14:45-15:45

ORANGE ROOM

### HANDS-ON WORKSHOPS

Eyes and Hypertension

Chairpersons: R. Boulestreau (Bordeaux, FRANCE), M. Paques (Paris, FRANCE),  
A. Zaleska-Zmijewska (Warsaw, POLAND)

14:45-14:55 Retinal Evaluation in Hypertension and Malignant Hypertension  
(MHT) - Clinical Relevance  
R. Boulestreau (Bordeaux, FRANCE)

14:55-15:05 Fundus in Hypertension  
A. Zaleska-Zmijewska (Warsaw, POLAND)

15:05-15:35 Workshop and Practical Cases  
M. Szczesniak (Warsaw, POLAND), N. Jurzak (Warsaw, POLAND)

15:35-15:45 Innovative Approaches in Retinal Evaluation  
M. Paques (Paris, FRANCE)



## FRIDAY, MAY 29, 2026

16:00-17:00

ORANGE ROOM

### HANDS-ON WORKSHOPS

#### Small Arteries and Hypertension

Chairpersons: R.M. Bruno (Paris, FRANCE), A. Virdis (Pisa, ITALY)

16:00-16:10 Microcirculation in Hypertension – Clinical Relevance  
A. Virdis (Pisa, ITALY)

16:10-16:20 How to assess Peripheral Microcirculation: Invasive Approaches  
A. Mengozzi (Pisa, ITALY)

16:20-16:30 How to assess Peripheral Microcirculation: Non-Invasive Approaches  
R.M. Bruno (Paris, FRANCE)

16:30-16:40 Innovative Approaches  
E. Hermeling (Eindhoven, THE NETHERLANDS)

16:40-17:00 Hands-On Session  
E. Hermeling (Eindhoven, THE NETHERLANDS)

10:00-10:45

MEET-THE-EXPERT HUB

### Session supported **by HILO BY AKTIIA**

A hands-on session with real devices and clinical reports to prepare you for cuffless BP monitoring in practice

Chairpersons: T. Almeida (Neuchâtel, SWITZERLAND),  
J. Sola (Neuchâtel, SWITZERLAND)

10:00-10:05 Cuffless blood pressure monitoring in practice: what it is, what it is not, and why it matters now  
J. Sola (Neuchâtel, SWITZERLAND)

10:05-10:10 Inside Hilo: who we are, what makes the technology different, and why clinicians can trust it  
T. Almeida (Neuchâtel, SWITZERLAND)

10:10-10:15 From physiology to proof: an overview of Hilo's clinical validation and evidence to date (a summary of pivotal clinical trials)  
J. Sola (Neuchâtel, SWITZERLAND)

10:15-10:20 Hands-on with Hilo: what patients actually experience in daily life with a BP wearable  
T. Almeida (Neuchâtel, SWITZERLAND)

10:25-10:30 Hands-on with Hilo: how clinicians access, interpret, and use cuffless BP data  
J. Sola (Neuchâtel, SWITZERLAND)

10:30-10:35 Hands-on with Hilo: how patients share cuffless BP data with their physicians  
T. Almeida (Neuchâtel, SWITZERLAND)

10:35-10:40 Beyond blood pressure: what real-world usage patterns reveal about patient behavior  
J. Sola (Neuchâtel, SWITZERLAND)

10:40-10:45 Q&A

11:30-11:50

MEET-THE-EXPERT HUB

### Meet-the-Expert supported **by MENARINI GROUP**

Targeting Sympathetic overdrive in hypertension: the choice of the right molecule

Expert: G. Grassi (Milan, ITALY)



## FRIDAY, MAY 29, 2026

12:10-12:30

MEET-THE-EXPERT HUB

*Meet-the-Expert supported by **BAUSCH HEALTH***

**One size never fits all: a case-based workshop for individualized obesity care**

Experts: A. Kurylowicz (Warsaw, POLAND), A. Prejbisz (Warsaw, POLAND),

12:45-13:30

MEET-THE-EXPERT HUB

*Session supported by **BOEHRINGER INGELHEIM***

**uACR testing in hypertension: Practical integration for proactive protection**

12:45-12:50 Arrivals and Pre-Session engagement

12:50-13:00 *Welcome and introduction: The uACR implementation imperative*

F. Mahfoud (Basel, SWITZERLAND),  
M. Papadakis (London, UNITED KINGDOM),  
S. Sinha (Manchester, UNITED KINGDOM)

13:00-13:10 Building a blueprint: Overcoming challenges to uACR integration

F. Mahfoud (Basel, SWITZERLAND),  
M. Papadakis (London, UNITED KINGDOM),  
S. Sinha (Manchester, UNITED KINGDOM)

13:10-13:25 Real-world uACR integration: An implementation case study

Speaker: S. Sinha (Manchester, UNITED KINGDOM)

Q&A Moderators: F. Mahfoud (Basel, SWITZERLAND),  
M. Papadakis (London, UNITED KINGDOM)

13:25-13:30 Moving forward: A collective commitment

F. Mahfoud (Basel, SWITZERLAND),  
M. Papadakis (London, UNITED KINGDOM),  
S. Sinha (Manchester, UNITED KINGDOM)

14:45-15:05

MEET-THE-EXPERT HUB

*Meet-the-Expert supported by **MEDTRONIC***

**Meet the RDN Expert - Interactive Discussion**

Expert: A. Pathak (Luxembourg, LUXEMBOURG)

16:00-16:20

MEET-THE-EXPERT HUB

*Meet-the-Expert supported by **MENARINI GROUP***

**Unmet needs beyond statin therapy**

Expert: M. Banach (Lublin, POLAND)

17:30-17:50

MEET-THE-EXPERT HUB

*Meet-the-Expert supported by **SERVIER***

**Innovation with quadruple SPC: a new standard in the Resistant Hypertension Patient Pathway**

Panelists: R. Kreutz (Berlin, GERMANY), A. Pathak (Luxembourg, LUXEMBOURG), S. Taddei (Pisa, ITALY)

17:30-17:35 Resistant Hypertension: Complexity at Scale

S. Taddei (Pisa, ITALY)

17:35-17:40 Addressing the Multifactorial Nature of Resistant Hypertension

R. Kreutz (Berlin, GERMANY)

17:40-17:45 Innovation Through Simplification: Redefining Treatment

Implementation with Quadruple SPC  
A. Pathak (Luxembourg, LUXEMBOURG)

17:45-17:50

Q&A



## FRIDAY, MAY 29, 2026

09.30-10.00

PATIENT JOURNEY / LEARNING ROOM

### **Expert Insight Session**

*This activity is provided by Nexus Healthcare Education and supported by an independent educational grant from AstraZeneca*

Practical strategies to facilitate adoption of ASIs  
R. Kreutz (Berlin, GERMANY)

15.30-16.00

PATIENT JOURNEY / LEARNING ROOM

### **Expert Insight Session**

*This activity is provided by Nexus Healthcare Education and supported by an independent educational grant from AstraZeneca*

From clinical trials to the clinic - How will ASIs be used in real-world practice?  
A. Schutte (Sydney, AUSTRALIA)

17.45-19.00

E-POSTER SESSIONS

Totem 1	Award Session
Totem 2	BP Measurement and Monitoring I
Totem 3	BP Measurement and Monitoring II
Totem 4	Brain
Totem 5	Children and Adolescents
Totem 6	Clinical Studies I
Totem 7	Diagnostics and Digital Health
Totem 8	Epidemiology I
Totem 9	Heart I
Totem 10	Hypertension Phenotypes I
Totem 11	Lifestyle Intervention
Totem 12	Older Persons
Totem 13	Pathophysiology and Mechanisms I
Totem 14	Pharmacotherapy I
Totem 15	Real-World Evidence Research I
Totem 16	Risk Factors I
Totem 17	Secondary Hypertension



~1 in 3

adults worldwide,  
approximately  
**1.4 billion people**,  
are affected by  
hypertension<sup>1,\*</sup>

Uncontrolled hypertension, a widely recognized risk factor for cardiovascular disease, may be aldosterone-driven.<sup>2,3</sup>

Dysregulated aldosterone may contribute to hypertension through both renin-angiotensin-aldosterone system (RAAS)-dependent and RAAS-independent signaling pathways.<sup>4-6</sup>



To learn more about the impact of dysregulated aldosterone in uncontrolled hypertension and its impact on patients...

**VISIT MINERALYS AT BOOTH #3**

\*Estimated by the World Health Organization in 2024. Adults are defined as individuals aged 30-79 years old.<sup>1</sup>

**References:** 1. World Health Organization. Hypertension. Published 2025. Accessed April 27, 2026. <https://www.who.int/news-room/fact-sheets/detail/hypertension> 2. Centers for Disease Control and Prevention. High blood pressure facts. Updated January 28, 2025. Accessed April 27, 2026. <https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html> 3. Buso G, Agabiti-Rosei C, Lemoli M, et al. *Eur Cardiol.* 2024;19:e07. doi:10.15420/ecr.2023.51 4. Kawarazaki W, Fujita T. *Am J Hypertens.* 2016;29(4):415-423. doi:10.1093/ajh/hpw003 5. Faulkner JL, Belin de Chantemèle EJ. *Vitam Horm.* 2019;109:265-284. doi:10.1016/bs.vh.2018.09.003 6. Cannavo A, Bencivenga L, Liccardo D, et al. *Oxid Med Cell Longev.* 2018;2018:1204598. doi:10.1155/2018/1204598

The content is intended for healthcare provider general disease education purposes only.

© 2026 Mineralys Therapeutics Inc. All Rights Reserved 04/2026  
LORHY-EMA029. Expiration: June 1, 2026



**ESH** Gdańsk  
2026

**SATURDAY, 28 MAY**





## SATURDAY, MAY 30, 2026

05:00-06:30

SOPOT

### SUNRISE SESSION

#### Wake Up Your Heart: How to Optimize Circadian Cardiometabolic Health

This special Sunrise Session will explore the relationship between circadian rhythms and cardiometabolic health in an inspiring and unconventional setting, combining science, wellbeing, and interaction in the early morning atmosphere of Sopot beach.

Faculty: T. Yates (Leicester, UNITED KINGDOM), G. Parati (Milan, ITALY), J. Wolf (Gdańsk, POLAND)

08:00-09:15

BLUE ROOM

### ORAL SESSION

#### Blood Pressure Monitoring

Chairpersons: A. de la Sierra (Terrasa, SPAIN),  
P. Lopez-Jaramillo (Bucaramanga, COLOMBIA)

- 08:00-08:09 ISOLATED SYSTOLIC HYPERTENSION AND ISOLATED DIASTOLIC HYPERTENSION IDENTIFIED WITH AMBULATORY BLOOD PRESSURE: LONGITUDINAL ASSOCIATION WITH CARDIOVASCULAR EVENTS IN THE YOUNG  
F. Saladini<sup>(1)</sup>, M. Rattazzi<sup>(1,2)</sup>, R. Buso<sup>(2)</sup>, A. Mazzer<sup>(2)</sup>, L. Mos<sup>(3)</sup>, O. Vriz<sup>(3)</sup>, P. Palatini<sup>(1)</sup>  
<sup>(1)</sup>Padua, <sup>(2)</sup>Treviso, <sup>(3)</sup>Udine (ITALY)
- 08:09-08:18 TWENTY-FOUR HOUR CENTRAL SYSTOLIC BLOOD PRESSURE IS A STRONGER PREDICTOR OF CARDIOVASCULAR EVENTS THAN TWENTY-FOUR HOUR BRACHIAL SYSTOLIC BLOOD PRESSURE  
S. Wassertheurer<sup>(1)</sup>, K. Danninger<sup>(2)</sup>, R. Binder<sup>(2)</sup>, A. Argyris<sup>(3)</sup>, A. Protogerou<sup>(3)</sup>, C. Mayer<sup>(1)</sup>, B. Hametner<sup>(1)</sup>, T. Weber<sup>(2)</sup>  
<sup>(1)</sup>Vienna, <sup>(2)</sup>Wels (AUSTRIA), <sup>(3)</sup>Athens (GREECE)

- 08:18-08:27 REVISITING BLOOD PRESSURE SCREENING IN PRIMARY CARE: THE VALUE OF A SINGLE CASUAL BLOOD PRESSURE MEASUREMENT  
N. Evangelidis<sup>(1)</sup>, E. Smyrnakis<sup>(1)</sup>, V. Gkolias<sup>(1)</sup>, M. Gavana<sup>(1)</sup>, I. Theodoropoulos<sup>(1)</sup>, D. Symintiridou<sup>(1)</sup>, M. Andreou<sup>(1)</sup>, S. Tsotoulidis<sup>(1)</sup>, S. Lamprou<sup>(1)</sup>, M. Dragasaki<sup>(1)</sup>, A. Botskariova<sup>(1)</sup>, A. Savvaidou<sup>(1)</sup>, P. Toboulidou<sup>(1)</sup>, S. Ouzouni<sup>(1)</sup>, A.-B. Haidich<sup>(1)</sup>, C. Savopoulos<sup>(1)</sup>, A. Kollias<sup>(2)</sup>, G.S. Stergiou<sup>(2)</sup>, M. Doumas<sup>(1)</sup>, A. Triantafyllou<sup>(1)</sup>  
<sup>(1)</sup>Thessaloniki, <sup>(2)</sup>Athens (GREECE)

- 08:27-08:36 REAL-WORLD IMPLEMENTATION AND CLINICAL IMPACT OF CUFFLESS AMBULATORY BLOOD PRESSURE MONITORING  
H.J. Joo, J.-J. Cha, J.H. Park, S.J. Hong, C.W. Yu, E.J. Kim  
Seoul (SOUTH KOREA)

- 08:36-08:51 **LECTURE**  
**The Role and Impact of Global Opportunistic BP Screening: Lessons from May Measurement Month**  
N. Poulter (London, UNITED KINGDOM)

- 08:51-09:00 EFFECT OF CLOTHING ON BLOOD PRESSURE MEASUREMENT ACCURACY: A CROSSOVER STUDY  
A. Laurinavicius, A. Belini, F. Cesena, F. Consolim-Colombo, J. Souza, P. Gutemberg, R. Nastari, M. Sousa  
São Paulo (BRAZIL)

- 09:00-09:15 *General Discussion*



## SATURDAY, MAY 30, 2026

09:30-10:30

BLUE ROOM

### Innovations in Medication Adherence

Chairpersons: M. Burnier (Lausanne, SWITZERLAND),  
P. Gupta (Leicester, UNITED KINGDOM)

09:30-09:45 Artificial Intelligence in Medication Adherence: How Far Can This  
Innovation Take Us?  
P. Kardas (Łódź, POLAND)

09:45-10:00 Smart Digital Tools for Real Patients: The Power of Personalized  
Adherence  
B. Vrijens (Liege, BELGIUM)

10:00-10:15 Interprofessional Education and collaboration to support  
Medication Adherence  
M.P. Schneider (Geneva, SWITZERLAND)

10:15-10:30 *General Discussion*

10:45-11:30

BLUE ROOM

### MINI-SYMPOSIUM SUPPORTED BY NOVO NORDISK

#### What Obesity Can Learn from Hypertension?

Speakers: K. Narkiewicz (Gdańsk, POLAND), A.M. Sharma (Berlin, GERMANY)

11:45-12:45

BLUE ROOM

### Cardiometabolic Innovations Beyond Hypertension – Keynote Lectures

Chairpersons: A.F. Dominiczak (Glasgow, UNITED KINGDOM),  
M. Doumas (Thessaloniki, GREECE)

11:45-12:05 **PRESENTATION OF ESH AWARDS:**  
Paul Milliez Award  
SOMNOmedics Young Investigators Award  
SkyLabs Established Researchers Award

12:05-12:25 **From Dream to Reality: Improving lives through Endothelin -  
Related Innovations**  
M. Clozel (Allschwil, SWITZERLAND)

12:25-12:45 **Giving the Heart a taste of its own medicine**  
J. Paton (Auckland, NEW ZEALAND)

12:50-13:25

BLUE ROOM

ESH General Assembly



## SATURDAY, MAY 30, 2026

14:45-15:45

BLUE ROOM

### Lipids, Glucose and Immunization in the Era of Innovation

Chairpersons: M. Bohm (Homburg, GERMANY),  
J. Lewandowski (Warsaw, POLAND)

14:45-15:00 Next-Generation Lipid Lowering  
A. Zambon (Padua, ITALY)

15:00-15:15 Digital and Pharmacologic Innovations in Diabetes  
L. Czupryniak (Warsaw, POLAND)

15:15-15:30 Immunization and Cardiovascular Protection: Evidence and Future  
Directions  
E. Botelho-Nevers (Lyon, FRANCE)

15:30-15:45 *General Discussion*

16:50-16:55 *Discussion*  
*Discussant: D. Guerrot (Rouen, FRANCE)*

16:55-17:10 KARDIA-3: Add-On Zilebesiran in Hypertension with High  
Cardiovascular Risk With and Without CKD  
B. Williams (London, UNITED KINGDOM)

17:10-17:15 *Discussion*  
*Discussant: M. Tomaszewski (Manchester, UNITED KINGDOM)*

17:15-17:30 Lorundrostat for Hypertension in CKD: Results from the LAUNCH-  
HTN Trial  
L. Vogt (Amsterdam, THE NETHERLANDS)

17:30-17:35 *Discussion*  
*Discussant: A. Wiecek (Katowice, POLAND)*

16:15-17:35

BLUE ROOM

### CLINICAL TRIALS

#### Hotline - Session 2

Chairpersons: M. Bohm (Homburg, GERMANY), M.L. Muiesan (Brescia, ITALY),  
K. Tsioufis (Athens, GREECE)

16:15-16:30 Blood Pressure Lowering and Cardiovascular Outcomes Across the  
CKD Spectrum: An Individual Participant Data Meta-analysis of 46  
Trials  
S. E. Kjeldsen (Oslo, NORWAY)

16:30-16:35 *Discussion*  
*Discussant: M. Brunström (Umeå, SWEDEN)*

16:35-16:50 Renal Denervation in Patients with Autosomal Dominant Polycystic  
Kidney Disease: First Results from the Randomized RDN-ADPKD  
Study  
R.E. Schmieder (Erlangen, GERMANY)

08:00-09:15

RED ROOM

### CLINICAL CASES - SESSION 2

#### Focus on other Clinical Entities than Secondary Hypertension

Chairpersons: M. Aleckovic-Halilovic (Tuzla, BOSNIA AND HERZEGOVINA),  
L. Obrycki (Warsaw, POLAND),  
D.J.L. van Twist (Sittard/Heerlen, THE NETHERLANDS)

08:00-08:20 Big Problems of the Smallest Patients - Long-Term Cardiovascular  
Consequences of Extreme Prematurity in a 17-Year-Old Boy  
A. Bielanicz (Warsaw, POLAND)

08:20-08:40 Young kidney donor with metabolic syndrome and MASLD  
M. Pjanic (Tuzla, BOSNIA AND HERZEGOVINA)

08:40-09:00 An Unusual Culprit Behind Orthostatic Hypertension  
H. Kalic (Sittard/Heerlen, THE NETHERLANDS)

09:00-09:15 *General Discussion*



## SATURDAY, MAY 30, 2026

09:30-10:30

RED ROOM

### Sleep Disruption and Cardio-Cerebral-Metabolic Risk

*Joint Session with EFIM (European Federation in Internal Medicine)*

Chairpersons: N. Montano (Milan, ITALY), K. Tsioufis (Athens, GREECE)

09:30-09:32 Introduction

K. Tsioufis (Athens, GREECE)

09:32-09:44 Autonomic Mechanisms of Cardiovascular Risk in Sleep Disturbances

N. Montano (Milan, ITALY)

09:44-09:56 Does inadequate sleep make you fat, sick and cognitively impaired?

V.K. Somers (Rochester, NY, USA)

09:56-10:08 CPAP and beyond - from better breathing to Cardiovascular Guidelines

J. Wolf (Gdańsk, POLAND)

10:08-10:20 When sleep fragments but breathing remains: Non-Apneic Disruption and Cardiovascular Implications

M. Pengo (Milan, ITALY)

10:20-10:30 *Panel Discussion*

10:45-11:30

RED ROOM

### MINI-SYMPOSIUM SUPPORTED by HILO BY AKTIIA

Still skeptical about cuffless BP monitoring? An evidence-based session built on the experience of over 200,000 Hilo patients and their doctors across Europe

Chairpersons: T.L. Bothe (Hobart, AUSTRALIA),  
G. Wuerzner (Lausanne, SWITZERLAND)

10:45-10:54 Do PPG signals truly contain blood pressure information? The physiological basis of modern cuffless BP monitoring  
J. Sola (Neuchâtel, SWITZERLAND)

10:54-11:03 Screening hypertension with cuffless technologies at global scale: from vision to reality  
T.L. Bothe (Hobart, AUSTRALIA)

11:03-11:12 Managing hypertension with cuffless technologies at individual scale: how patient empowerment translates into better blood pressure control  
T. Almeida (Neuchâtel, SWITZERLAND)

11:12-11:21 Integrating cuffless technologies into clinical workflows: lessons from five years of real-world experience in Switzerland  
G. Wuerzner (Lausanne, SWITZERLAND)

11:21-11:30 *Round Table*



## SATURDAY, MAY 30, 2026

11:45-12:45

RED ROOM

### DOCTOR, CAN I...?

Practical answers to real-world hypertension dilemmas (part 2)

*Joint Session with the Polish Society of Hypertension*

Chairpersons: E. Rodilla Sala (Valencia, SPAIN)  
J. Wolf (Gdańsk, POLAND)

11:45-11:50 After preeclampsia - what is the risk in my next pregnancy?  
A. Szyndler (Gdańsk, POLAND)

11:50-11:55 When should I measure BP: before or after medication?  
J. Nemcsik (Budapest, HUNGARY)

11:55-12:00 Which painkillers are safe if I have hypertension?  
N. Muñoz Rivas (Madrid, SPAIN)

12:00-12:05 Which supplements, if any, help with hypertension?  
A. Biesiada (Kraków, POLAND)

12:05-12:10 Does vitamin D really lower blood pressure?  
V. Cunha (Almada, PORTUGAL)

12:10-12:15 Is coffee safe if I have high blood pressure?  
S. Surma (Katowice, POLAND)

12:15-12:20 Can weight loss reduce or stop my blood pressure medication?  
S. Cinza Sanjurjo (Santiago de Compostela, SPAIN)

12:20-12:25 I have hypertension - can I run a half marathon?  
M. Klocek (Kraków, POLAND)

12:25-12:45 *General Discussion*

13:30-14:30

RED ROOM

### SYMPOSIUM SUPPORTED BY **BOEHRINGER INGELHEIM**

Beyond hypertension: Is albuminuria the missing marker of CV risk?

Chairperson: M. Azizi (Paris, FRANCE)

13:30-13:33 Welcome and introduction  
M. Azizi (Paris, FRANCE)

13:33-13:48 Under pressure: The importance of albuminuria in hypertension  
management  
F. Mahfoud (Basel, SWITZERLAND)

13:48-14:03 Unfiltered: The crucial role of albuminuria for the diagnosis and  
management of CKD  
S. Sinha (Manchester, UNITED KINGDOM)

14:03-14:18 Pulse check: Leveraging uACR for CV risk detection and improved  
outcomes  
M. Papadakis (London, UNITED KINGDOM)

14:18-14:28 *Panel discussion: Strategies to improve heart and kidney health in  
patients with hypertension*

Speakers: F. Mahfoud (Basel, SWITZERLAND),  
M. Papadakis (London, UNITED KINGDOM),  
S. Sinha (Manchester, UNITED KINGDOM)

Moderator: M. Azizi (Paris, FRANCE)

14:28-14:30 Closing remarks  
M. Azizi (Paris, FRANCE)



## SATURDAY, MAY 30, 2026

14:45-16:00

RED ROOM

### How to adopt hypertension guidelines into clinical practice: What works in my country

Chairpersons: T. Weber (Wels, AUSTRIA),  
R. de Pinho (São João da Madeira, PORTUGAL)

Introduction R. de Pinho (São João da Madeira, PORTUGAL),  
T. Weber (Wels, AUSTRIA)

WHO perspective K.M. Agboyibor (WHO, Geneva, SWITZERLAND)

Argentina N. Renna (Mendoza, ARGENTINA)

Australia A. Schutte (Sydney, AUSTRALIA)

Brazil W. Nadruz Jr (Campinas, BRAZIL)

Canada S. Daskalopoulou (Montreal, CANADA)

China Y. Zhang (Beijing, CHINA)

Nigeria D. Ojji (Gwagwalada, Abuja, NIGERIA)

Slovak Republic A. Vachulova (Bratislava, SLOVAK REPUBLIC)

South Korea K.-i. Kim (Seongnam, SOUTH KOREA)

#### Q&A Discussion

Discussants: R. Kreutz (Berlin, GERMANY), G. Parati (Milan, ITALY)

16:15-17:30

RED ROOM

### ORAL SESSION

#### Global and Environmental Determinants of Blood Pressure

Chairpersons: V. Ram (Irving, TX, USA), W. Wojciechowska (Kraków, POLAND)

16:15-16:30 **LECTURE**

#### The Interplay between Mental Health and Cardiovascular Disease in the Context of Climate - Related Exposures

L. Kuzma (Białystok, POLAND)

16:30-16:39 GLOBAL PATTERNS AND REGIONAL DIFFERENCES IN ISOLATED SYSTOLIC HYPERTENSION AMONG UNTREATED HYPERTENSIVE ADULTS: A CROSS-SECTIONAL ANALYSIS OF THE MAY MEASUREMENT MONTH 2022

X. Wang<sup>(1)</sup>, T. Beaney<sup>(1)</sup>, G. Kerr<sup>(1)</sup>, M. Schlaich<sup>(2)</sup>, A. Schutte<sup>(3,4)</sup>,  
G. S. Stergiou<sup>(5)</sup>, N. Poulter<sup>(1)</sup>

<sup>(1)</sup> London (UNITED KINGDOM), <sup>(2)</sup> Perth, <sup>(3)</sup> Sydney (AUSTRALIA),  
<sup>(4)</sup> Potchefstroom (SOUTH AFRICA), <sup>(5)</sup> Athens (GREECE)

16:39-16:48 GLOBAL PERSPECTIVES ON BLOOD PRESSURE AND STROKE RISK: A SYSTEMATIC REVIEW COMPARING ASIAN AND WESTERN POPULATIONS

K. Tsoi<sup>(1)</sup>, Y. Hu<sup>(1)</sup>, Z. Hao<sup>(1)</sup>, K. Yiu<sup>(1)</sup>, H.-M. Cheng<sup>(2)</sup>, J. Wang<sup>(3)</sup>, K. Kario<sup>(4)</sup>

<sup>(1)</sup> Hong Kong, <sup>(2)</sup> Taiwan, <sup>(3)</sup> Shanghai (CHINA), <sup>(4)</sup> Tochigi-ken (JAPAN)

16:48-16:57 CO-OCCURRENCE OF CARDIOVASCULAR-KIDNEY-METABOLIC CONDITIONS IN THE MAY MEASUREMENT MONTH GLOBAL CAMPAIGN 2023

G. Kerr<sup>(1)</sup>, T. Beaney<sup>(1)</sup>, M. Schlaich<sup>(2)</sup>, A. Schutte<sup>(3,4)</sup>,  
G. S. Stergiou<sup>(5)</sup>, N. Poulter<sup>(1)</sup>

<sup>(1)</sup> London (UNITED KINGDOM), <sup>(2)</sup> Perth, <sup>(3)</sup> Sydney (AUSTRALIA), <sup>(4)</sup>  
Potchefstroom (SOUTH AFRICA), <sup>(5)</sup> Athens (GREECE)



## SATURDAY, MAY 30, 2026

16:57-17:00 AMBIENT TEMPERATURE, SEASONAL VARIATIONS, AND BLOOD PRESSURE. EHUH 2 STUDY  
A. Vuksic<sup>(1)</sup>, J. Nikic<sup>(1)</sup>, A. Jelakovic<sup>(1)</sup>, I. Abramovic<sup>(1)</sup>, D. Bakovic<sup>(1)</sup>, A. Stupin<sup>(2)</sup>, G. Gajski<sup>(1)</sup>, N. Vikić-Topic<sup>(1)</sup>, L. Srnec<sup>(1)</sup>, I. Herceg Bulić<sup>(1)</sup>, M. Marinovic Glavic<sup>(3)</sup>, L. Bilajac<sup>(3)</sup>, Z. Reiner<sup>(1)</sup>, I. Pecin<sup>(1)</sup>, B. Jelakovic<sup>(1)</sup>  
<sup>(1)</sup>Zagreb, <sup>(2)</sup>Osijek, <sup>(3)</sup>Rijeka (CROATIA)

17:06-17:15 NATIONWIDE LONG-TERM EXPOSURE TO NITROGEN DIOXIDE AND CARDIOVASCULAR DISEASE MORTALITY IN CHINA: A 11-YEAR COHORT STUDY  
Z. Zhou<sup>(1)</sup>, X. Yu<sup>(2)</sup>, J. Qi<sup>(1)</sup>, Y. Liu<sup>(1)</sup>, M. Zhou<sup>(1)</sup>, L. Wang<sup>(1)</sup>  
<sup>(1)</sup>Beijing, <sup>(2)</sup>Yantai (CHINA)

17:15-17:24 COFFEE DRINKING IS LONGITUDINALLY ASSOCIATED WITH INCREASED RISK OF HYPERTENSION IN YOUNG INDIVIDUALS WITH ELEVATED SYMPATHO-ADRENERGIC ACTIVITY  
F. Saladini<sup>(1)</sup>, M. Rattazzi<sup>(1,2)</sup>, G. Garavelli<sup>(3)</sup>, S. Cozzio<sup>(4)</sup>, G. Berton<sup>(2)</sup>, P. Palatini<sup>(1)</sup>  
<sup>(1)</sup>Padua, <sup>(2)</sup>Treviso, <sup>(3)</sup>Cremona, <sup>(4)</sup>Rovereto (ITALY)

17:24-17:30 *General Discussion*

08:00-09:15

YELLOW ROOM

### ORAL SESSION

#### Real-World Evidence

Chairpersons: C. Koppelstätter (Innsbruck, AUSTRIA),  
A.J. Manolis (Athens, GREECE)

08:00-08:09 BENEFITS AND HARMS OF ANTIHYPERTENSIVE TREATMENT ACCORDING TO AGE, SEX, FRAILITY AND HISTORY OF CARDIOVASCULAR DISEASE: A MODELLING STUDY IN 5.5 MILLION ELECTRONIC HEALTH RECORDS

J.P.S. Sheppard<sup>(1)</sup>, A. Wang<sup>(1)</sup>, C. Koshiaris<sup>(2)</sup>, N. Gould<sup>(1)</sup>, L. Archer<sup>(3)</sup>, A. Banerjee<sup>(4)</sup>, B. Bellows<sup>(5)</sup>, C. Clark<sup>(6)</sup>, A. Clegg<sup>(7)</sup>, F.D.R. Hobbs<sup>(1)</sup>, J. Mant<sup>(8)</sup>, R. Payne<sup>(6)</sup>, R. Stevens<sup>(1)</sup>, Treadwell<sup>(9)</sup>, J. Usher-Smith<sup>(8)</sup>, R. McManus<sup>(10)</sup>  
<sup>(1)</sup>Oxford (UNITED KINGDOM), <sup>(2)</sup>Nicosia (CYPRUS), <sup>(3)</sup>Birmingham, <sup>(4)</sup>London (UNITED KINGDOM), <sup>(5)</sup>New York, NY, (USA), <sup>(6)</sup>Exeter, <sup>(7)</sup>Leeds, <sup>(8)</sup>Cambridge, <sup>(9)</sup>Bristol, <sup>(10)</sup>Brighton (UNITED KINGDOM)

08:09-08:18 NATIONWIDE IMPACT OF ADDING AN ADDITIONAL ANTIHYPERTENSIVE AGENT IN TREATED PATIENTS WITH UNCONTROLLED HYPERTENSION

V. Olié<sup>(1)</sup>, C. Grave<sup>(2)</sup>, C. Bonaldi<sup>(2)</sup>, L. Carcaillon-Bentata<sup>(3)</sup>, J. Blacher<sup>(4)</sup>  
<sup>(1)</sup>Saint-Denis, <sup>(2)</sup>Saint-Maurice, <sup>(3)</sup>Bordeaux, <sup>(4)</sup>Paris (FRANCE)

08:18-08:27 BOSPHORE STUDY: COMPARATIVE EFFECTIVENESS OF TRIPLE THERAPY -BISOPROLOL, PERINDOPRIL, AMLODIPINE- VERSUS DUAL THERAPY IN UNCONTROLLED HYPERTENSIVE PATIENTS: AN OBSERVATIONAL COHORT

K. Tsioufis<sup>(1)</sup>, C. Darricarere<sup>(2)</sup>, C. Ariti<sup>(3)</sup>, A. Sartorius<sup>(3)</sup>, C. Apert-Maarek<sup>(4)</sup>, S. Birot<sup>(5)</sup>, K. Aroui<sup>(2)</sup>, T.M. MacDonald<sup>(6)</sup>  
<sup>(1)</sup>Athens (GREECE), <sup>(2)</sup>Paris (FRANCE), <sup>(3)</sup>Madrid (SPAIN), <sup>(4)</sup>Saclay (FRANCE), <sup>(5)</sup>Dundee (UNITED KINGDOM)



## SATURDAY, MAY 30, 2026

08:27-08:42 **LECTURE: How Can Real - World Data Redefine Clinical Practice?**

T. Zdrojewski (Gdańsk, POLAND)

08:42-08:51 REAL-WORLD ANALYSIS OF ADHERENCE, PERSISTENCE AND OUTCOMES IN PATIENTS RECEIVING QUADRUPLE THERAPY WITH PERINDOPRIL, INDAPAMIDE, AMLODIPINE AND BISOPROLOL IN ITALY

G. Desideri<sup>(1)</sup>, G. Mancia<sup>(2)</sup>, S. Brouwers (3,4), S. Calabria<sup>(5)</sup>,

M. Leogrande<sup>(5)</sup>, L. Degli Esposti<sup>(5)</sup>, K. Narkiewicz<sup>(6)</sup>

<sup>(1)</sup> Rome, <sup>(2)</sup> Milan (ITALY), <sup>(3)</sup> Aalst, <sup>(4)</sup> Brussels (BELGIUM), <sup>(5)</sup>

Bologna (ITALY), <sup>(6)</sup> Gdańsk (POLAND)

08:51-09:00 COMPARATIVE EFFECTIVENESS OF SPIRONOLACTONE VERSUS BETA-BLOCKERS AS FOURTH-LINE THERAPY IN RESISTANT HYPERTENSION: IMPACT ON ALBUMINURIA IN A REAL-WORLD SETTING

A.G. Laurinavicius, I. Aguiar, P. Gutemberg, G. Laurinavicius,

R. Nastari, J. Souza, M. Sousa

São Paulo (BRAZIL)

09:00-09:09 EXERCISE BLOOD PRESSURE PROFILES AND MORTALITY RISK IN HEART FAILURE: INSIGHTS FROM CARDIOPULMONARY EXERCISE TESTING

M. Kariori, C. Fragoulis, I. Leontsinis, P. Xydis, E. Dri, P. Iliakis, M.

Kouremeti, T. Kalos, D. Konstantinidis, C. Chrysochoou, K. Tsioufis

Athens (GREECE)

09:30-10:30

YELLOW ROOM

**Salt, Inflammation, the Skin and the Kidney: Hope or Hype**

Chairpersons: F. Jarraya (Sfax, TUNISIA /Montélimar, FRANCE),

U. Wenzel (Hamburg, GERMANY)

09:30-09:45 Na<sup>+</sup> sensitive hypertension and the lymphatic system

G. Rossitto (Padua, ITALY)

09:45-10:00 Heparan sulfation and salt sensitivity

R. Olde Engberink (Amsterdam, THE NETHERLANDS)

10:00-10:15 New connections between polygenic and monogenic human

disease through the lens of kidney multi-omics

M. Tomaszewski (Manchester, UNITED KINGDOM)

10:15-10:30 *General Discussion*

10:45-11:30

YELLOW ROOM

**MINI-SYMPOSIUM SUPPORTED BY SERVIER**

**Managing the Complex Hypertensive Patients in a Multi-morbid World - Round Table Discussion**

Chairperson: G. Savarese (Graz-Stockholm, SWEDEN)

Panelists: K. Hafidh (Dubai, UNITED ARAB EMIRATES), S. Masi (Pisa, ITALY),

M. Strauss (Toronto, CANADA)

10:45-10:49 Introduction

G. Savarese (Graz-Stockholm, SWEDEN)

10:49-11:01 Managing Multimorbidity Hypertension: Endpoints Do Matter

K. Hafidh (Dubai, UNITED ARAB EMIRATES)

11:01-11:13 Why Cardiovascular Mortality Tells a Different Story in

Hypertension?

S. Masi (Pisa, ITALY)

11:13-11:25 Making Sense of RAAS Inhibition: Insights from Recent

Meta-Analysis

M. Strauss (Toronto, CANADA)

11:25-11:30 Conclusion

G. Savarese (Graz-Stockholm, SWEDEN)



## SATURDAY, MAY 30, 2026

13:30-14:30

YELLOW ROOM

### SYMPOSIUM SUPPORTED **BY KRKA**

The impact of single-pill combinations in hypertension management - novel insights

Chairperson: R. Kreutz (Berlin, GERMANY)

13:30-13:35 Introduction  
R. Kreutz (Berlin, GERMANY)

13:35-13:45 The PRECIOUS trial: Sex differences in hypertension treatment  
J. Brguljan Hitij (Ljubljana, SLOVENIA)

13:45-13:55 The SATELLITE trial: The hidden dimension of hypertension control  
K.J. Filipiak (Warsaw, POLAND)

13:55-14:07 The INDependent study: First real-world experience with an ARB/  
Indapamide single-pill combination  
A. Januszewicz (Warsaw, POLAND)

14:07-14:25 *Panel discussion*

14:25-14:30 Closing remarks  
R. Kreutz (Berlin, GERMANY)

14:45-15:45

YELLOW ROOM

### The Immune System in Hypertension: Driver, Amplifier, or Bystander?

Chairpersons: A.H.J. Danser (Rotterdam, THE NETHERLANDS),  
T. Guzik (Kraków, POLAND/Edinburgh, UNITED KINGDOM)

14:45-15:00 Immune System and Hypertension: From Basic Discovery to  
Treatable Endotypes  
T. Guzik (Kraków, POLAND/Edinburgh, UNITED KINGDOM)

15:00-15:15 Immune Mechanisms and the Brain-Heart Axis in Hypertension  
D. Carnevale (Pozzilli/Rome, ITALY)

15:15-15:30 Cytokines and Hypertension  
J. Stegbauer (Duesseldorf, GERMANY)

15:30-15:45 *General Discussion*

16:15-17:30

YELLOW ROOM

### ORAL SESSION

#### Secondary Hypertension

Chairpersons: J. Kadziela (Warsaw, POLAND),  
D. Van Twist (Sittard/Heerlen, THE NETHERLANDS)

16:15-16:24 SENSITIVE DIAGNOSTIC THRESHOLDS IN THE MANAGEMENT OF  
PRIMARY ALDOSTERONISM  
P. Kmieć, J. Fiszler, J. Tarnowska, S. Zembrzuska,  
R. Swiatkowska-Stodulska  
Gdańsk (POLAND)

16:24-16:33 EUROPEAN SOCIETY OF ENDOCRINOLOGY 2025 CRITERIA DOUBLE  
PRIMARY ALDOSTERONISM DETECTION IN HYPERTENSIVE  
PATIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY  
E.-M. Cordeanu, C. Cherdo, C. Mirea, S. Brouder, C. Zamperini,  
D. Stephan  
Strasbourg (FRANCE)



## SATURDAY, MAY 30, 2026

- 16:33-16:42 DIFFERENTIAL MEDIATION OF VASCULAR DAMAGE BY CENTRAL BLOOD PRESSURE IN PRIMARY ALDOSTERONISM  
G.E. Sabbà, A. Franzin, V. Zanconato, F. Stocchetti, S. Grisenti, F. Bertucci, A. Giontella, M.N. Guler, S. Bonafini, C. Fava  
Verona (ITALY)
- 16:42-16:57 **LECTURE**  
**A Critical Appraisal of Biochemical Phenotyping of Hyperaldosteronism**  
T.M. Seccia (Padua, ITALY)
- 16:57-17:06 THE RELATIONSHIP BETWEEN SURGICAL OUTCOMES AND KCNJ5 MUTATIONS AND PATHOLOGICAL CLASSIFICATION IN PATIENTS WITH UNILATERAL PRIMARY  
Y. Ma, J. Xu, L. Zhu, J. Wang  
Shanghai (CHINA)
- 17:06-17:15 SURGICAL VERSUS MEDICAL TREATMENT OF PRIMARY ALDOSTERONISM: COMPARATIVE EFFECTS ON LONG-TERM BLOOD PRESSURE OUTCOMES FROM A META-ANALYTIC PERSPECTIVE  
F. Zoccatelli, G. Costa, L. Panepinto, M. Merlo, F. Pizzolo, S. Friso, L. Marzano  
Verona (ITALY)
- 17:15-17:24 COMPUTATIONAL FLUID DYNAMICS FOR SELECTING PATIENTS TO TREAT WITH RENAL ARTERY STENOSIS  
L. Van de Velde, T.A. Bouwmeester, D. Collard, I.A. Zijlstra, A.B. Lamers, L. Vogt, B.H. van den Born  
Amsterdam (THE NETHERLANDS)
- 17:24-17:30 *General Discussion*

08:00-09:15

PURPLE ROOM

### ORAL SESSION

#### Clinical Innovations

Chairpersons: M. Bursztyn (Jerusalem, ISRAEL),  
J. Versmissen (Rotterdam, THE NETHERLANDS)

- 08:00-08:09 DEVELOPMENT OF A NOVEL DIGITAL PHARMACOKINETICS APP FOR CARDIOVASCULAR DRUGS  
A. Akram, R. Al Ghamdi, D. Lane, D. Bernieh, D.J. Jones, P. Gupta  
Leicester (UNITED KINGDOM)
- 08:09-08:18 ONLINE EDUCATION USING EXPERT DISCUSSION AND VISUAL ANIMATION IMPROVES CLINICIAN UNDERSTANDING OF UNMET NEEDS AND EMERGING MECHANISMS IN HYPERTENSION MANAGEMENT  
L. Thevathasan<sup>(1)</sup>, G. Montanero<sup>(2)</sup>, G. O'Malley<sup>(1)</sup>, K. Reid<sup>(1)</sup>  
<sup>(1)</sup>London (UNITED KINGDOM), <sup>(2)</sup>New York, NY, (USA)
- 08:18-08:33 **LECTURE**  
**Incretin-Mediated Blood Pressure Lowering: Driven by Weight Loss or Direct Tissue Effects?**  
U. Wenzel (Hamburg, GERMANY)
- 08:33-08:42 A RANDOMISED CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF GUT MICROBIOME MODULATION IN LOWERING BLOOD PRESSURE IN PRE-HYPERTENSIVE PATIENTS  
A.B. Shah  
Valsad (INDIA)
- 08:42-08:51 ROLE OF ANGIOTENSIN RECEPTOR BLOCKER THERAPY IN EPILEPTIC SEIZURE INCIDENCE IN PATIENTS AFTER ACUTE STROKE – RESULTS OF A NON-INTERVENTIONAL STUDY  
Z. Kiss, B. Fülöp, Z. Hermann, B. Jassoy, A. Koszta, K. Kovács-Kusza, K. Magyar-Zuberecz, E. Pordány-Bagoly, K. Radó, D.E. Dani, G. Szegleti, V. Varga, Z. Szupera  
Budapest (HUNGARY)



## SATURDAY, MAY 30, 2026

08:51-09:00 THERAPEUTIC POTENTIAL OF FAECALIBACTERIUM PRAUSNITZII IN  
HYPERTENSION-INDUCED CARDIORENAL DAMAGE  
N. Haase, T. Nurana, G.N. Kaufhold, S.M. Kedziora, D.N. Müller  
Berlin (GERMANY)

09.00-09.15 *General Discussion*

09:30-10:30 PURPLE ROOM

### Smarter Trial Design to accelerate Clinical Science

Chairpersons: M. Azizi (Paris, FRANCE), M. Brunström (Umeå, SWEDEN)

09:30-09:45 Emulating Randomized Trials using Real-World Data  
A. Douros (Berlin, GERMANY)

09:45-10:00 In-Silico Trials: A Tool to Predict Drugs' Effects  
T. Angoulvant (Tours, FRANCE)

10:00-10:15 Decentralized Clinical Trials  
I. Mackenzie (Dundee, UNITED KINGDOM)

10:15-10:30 *General Discussion*

10:45-11:30

PURPLE ROOM

### MINI-SYMPOSIUM SUPPORTED **BY MINERALYS**

Targeting Dysregulated Aldosterone in Hypertension and Cardio-Renal-  
Metabolic Syndrome: The Unmet Clinical Need

10:45-10:50 Introductions  
M. Saxena (London, UNITED KINGDOM)

10:50-11:00 Unmet clinical need in uncontrolled and resistant hypertension  
C. Borghi (Bologna, ITALY)

11:00-11:10 Role of dysregulated aldosterone in hypertension and  
cardiovascular-renal diseases  
L. Vogt (Amsterdam, THE NETHERLANDS)

11:10-11:25 Panel Discussion: Treatment options to target dysregulated  
aldosterone  
M. Saxena (London, UNITED KINGDOM)

11:25-11:30 Q & A  
C. Borghi (Bologna, ITALY)



## SATURDAY, MAY 30, 2026

14:45-15:45

PURPLE ROOM

### PRO/CON DEBATE

Optimal BP target in people 80 years and beyond

*Joint Session with EuGMS (European Geriatric Medicine Society)*

Chairpersons: C. Rajkumar (Brighton, UNITED KINGDOM), H. Ribeiro (Oliveira de Azemeis, PORTUGAL)

14:45-14:50 Introduction  
C. Rajkumar (Brighton, UNITED KINGDOM)

14:50-15:05 <130 mmHg  
M. Brunström (Umeå, SWEDEN)

15:05-15:20 SBP>130 mmHg  
F. Mattace-Raso (Rotterdam, THE NETHERLANDS)

15:20-15:40 Panel Discussion and Q&A  
G. Bahat (Istanbul, TURKEY), A. Benetos (Nancy, FRANCE)

15:40-15:45 Summary  
H. Ribeiro (Oliveira de Azemeis, PORTUGAL)

16:15-17:30

PURPLE ROOM

### ORAL SESSION

Early-Life Hypertension

Chairpersons: D. Drozd (Kraków, POLAND), P.M. Nilsson (Malmö, SWEDEN)

16:15-16:24 SEX DIFFERENCES IN CHILDREN AND ADOLESCENTS WITH HYPERTENSION

A. Bielanicz<sup>(1)</sup>, M. Sikorski<sup>(1)</sup>, J. Koziej<sup>(1)</sup>, K. Skoczynski<sup>(1)</sup>, K. Mitoraj<sup>(1)</sup>, A. Blazejczyk<sup>(1)</sup>, M. Brzeska<sup>(1)</sup>, K. Dabrowski<sup>(1)</sup>, J. Feber<sup>(2)</sup>, M. Litwin<sup>(1)</sup>, L. Obrycki<sup>(1)</sup>

(1) Warsaw (POLAND), (2) Ottawa (CANADA)

16:24-16:33 THE RELATIONSHIP BETWEEN KIDNEY SIZE AND BLOOD PRESSURE VALUES IN CHILDREN WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

M. Brzeska<sup>(1)</sup>, K. Skoczynski<sup>(1)</sup>, M. Sikorski<sup>(1)</sup>, A. Blazejczyk<sup>(1)</sup>, A. Bielanicz<sup>(1)</sup>, K. Dabrowski<sup>(1)</sup>, J. Koziej<sup>(1)</sup>, J. Feber (2,3), M. Litwin<sup>(1)</sup>, L. Obrycki<sup>(1)</sup>

(1) Warsaw (POLAND), (2) Ottawa (CANADA), (3) Ostrava (CZECH REP.)

16:33-16:42 PREVALENCE OF WHITE COAT HYPERTENSION AND WHITE COAT EFFECT IN HEALTHY AND HYPERTENSIVE PREGNANCY

L. Szczepaniak-Chichel, D. Lipski, P. Uruski, A. Tykarski  
Poznań (POLAND)

16:42-16:51 AMBULATORY BLOOD PRESSURE MONITORING DEFINES HYPERTENSION PHENOTYPES AND PREDICTS A COMPOSITE ADVERSE PREGNANCY OUTCOME

M. Santos Silva, T. Aguiar, I. Cruz, C. Costa, S. Carvalho, A. Faustino, J. Mesquita Bastos  
Aveiro (PORTUGAL)

16:51-17:06 **LECTURE**

**Genetics of Early - Life Hypertension: From Risk to Mechanisms**

P. Munroe (London, UNITED KINGDOM)



## SATURDAY, MAY 30, 2026

17:06-17:15 PLACENTAL TRANSFER OF THE NOVEL ENDOTHELIN-1 RECEPTOR ANTAGONIST APROCITENTAN  
M.S. Harhangi<sup>(1)</sup>, A.C.M. Kluivers<sup>(1)</sup>, L. Tan<sup>(1)</sup>, L.E. van der Meeren<sup>(1,2)</sup>, M. Broekhuizen<sup>(1)</sup>, S. Delahay<sup>(3)</sup>, A.H.J. Danser<sup>(1)</sup>  
<sup>(1)</sup>Rotterdam, <sup>(2)</sup>Leiden (THE NETHERLANDS), <sup>(3)</sup>Allschwil (SWITZERLAND)

17:15-17:30 *General Discussion*

08:00-09:15

GREEN ROOM

### ORAL SESSION

#### Clinical Predictors of Cardiovascular Risk

Chairpersons: E. Agabiti Rosei (Brescia, ITALY), T. De Backer (Gent, BELGIUM)

08:00-08:15 **LECTURE**  
**Carotid Wall Sublayers: Novel Imaging Markers of Vascular Remodeling in Hypertension?**  
W. Nadruz Jr (Campinas, BRAZIL)

08:15-08:24 OSCILLOMETRIC AORTIC PULSE WAVE VELOCITY PREDICTS CARDIOVASCULAR OUTCOMES IN A MULTIETHNIC URBAN POPULATION, THE HELIUS STUDY  
G. Wijntjens, T. Bouwmeester, A. Dehghani, H. Galenkamp, F. Schaafsma, B.-J. van den Born  
Amsterdam (THE NETHERLANDS)

08:24-08:33 MANAgeing HYPERTENSION AMONG PEOPLE LIVING WITH HIV: AN INTEGRATED MODEL TRIAL  
D. Ojji <sup>(1)</sup>, A. Aifah<sup>(2)</sup>, E. Hade<sup>(2)</sup>, W. Chen<sup>(2)</sup>, A. Ekanem<sup>(3)</sup>, D. Henry<sup>(1)</sup>, S. Mishra<sup>(2)</sup>, N. Kanneh<sup>(2)</sup>, D. Onakomaiya<sup>(2)</sup>, S. Emmanuel<sup>(1)</sup>, E. Okon<sup>(1)</sup>, D. Ekpoudom<sup>(1)</sup>, I. Itun<sup>(1)</sup>, S. Osagie<sup>(4)</sup>, A. Orji<sup>(1)</sup>, A. Adedokun<sup>(1)</sup>, D. Lew<sup>(5)</sup>, A. Attah<sup>(3)</sup>, J. Iwelunmor<sup>(2)</sup>, O. Ogedegbe<sup>(2)</sup>  
<sup>(1)</sup>Gwagwalada, Abuja (NIGERIA), <sup>(2)</sup>New York, NY, (USA), <sup>(3)</sup>Uyo, <sup>(4)</sup>Abuja (NIGERIA), <sup>(5)</sup>Saint Louis, MO, (USA)

08:33-08:42 PULSE WAVE VELOCITY AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL DYNAMICS AFTER SUCCESSFUL REVASCULARIZATION– IMPACT ON PROGNOSIS IN EXTREME CARDIOVASCULAR RISK  
A. Postadzhiyan<sup>(1)</sup>, Y. Yotov<sup>(2)</sup>, S. Tisheva-Gospodinova<sup>(3)</sup>, F. Nikolov<sup>(4)</sup>, K. Ramshev<sup>(1)</sup>, D. Boychev<sup>(1)</sup>  
<sup>(1)</sup>Sofia, <sup>(2)</sup>Varna, <sup>(3)</sup>Pleven, <sup>(4)</sup>Plovdiv (BULGARIA)

08:42-08:51 THE DEVELOPMENT AND VALIDATION OF A CLINICAL PREDICTION MODEL FOR CARDIOVASCULAR RISKS: THE STRATIFY-CVD RISK PREDICTION MODEL  
A. Wang<sup>(1)</sup>, C. Koshiaris<sup>(2)</sup>, N. Gould<sup>(1)</sup>, L. Archer<sup>(3)</sup>, A. Banerjee<sup>(4)</sup>, B.K. Bellows<sup>(5)</sup>, C.E. Clark<sup>(6)</sup>, A. Clegg<sup>(7)</sup>, F.D.R. Hobbs<sup>(1)</sup>, J. Mant<sup>(8)</sup>, R.J. McManus <sup>(1,9)</sup>, R.A. Payne<sup>(6)</sup>, R. Stevens<sup>(1)</sup>, J. Treadwell<sup>(10)</sup>, J. Usher-Smith<sup>(8)</sup>, J.P. Sheppard<sup>(1)</sup>  
<sup>(1)</sup>Oxford (UNITED KINGDOM), <sup>(2)</sup>Nicosia (CYPRUS), <sup>(3)</sup>Birmingham, <sup>(4)</sup>London (UNITED KINGDOM), <sup>(5)</sup>New York, NY, (USA), <sup>(6)</sup>Exeter, <sup>(7)</sup>Bradford, <sup>(8)</sup>Cambridge, <sup>(9)</sup>Brighton, <sup>(10)</sup>Bristol (UNITED KINGDOM)

08:51-09:00 THE IMPACT OF AFFECTIVE TEMPERAMENTS ON TOTAL MORTALITY AND CARDIOVASCULAR OUTCOME IN PATIENTS WITH HYPERTENSION  
J. Nemcsik<sup>(1)</sup>, Zsarnai A. M. <sup>(1)</sup>, J. Takács<sup>(1)</sup>, A. László<sup>(2)</sup>, H. Gyöngyösi<sup>(1)</sup>, D. Batta<sup>(1)</sup>, Z. Nemcsik-Bencze<sup>(1)</sup>, P. Torzsa<sup>(1)</sup>, A. Makkos<sup>(1)</sup>, X. Gonda<sup>(1)</sup>, Z. Rihmer<sup>(1)</sup>  
<sup>(1)</sup>Budapest (HUNGARY), <sup>(2)</sup>Nuremberg (GERMANY)

09:00-09:09 ESH 2025 YOUNG INVESTIGATOR AWARD STUDY: NOCTURNAL BLOOD PRESSURE FLUCTUATIONS AND NON-DIPPING PATTERNS IN OSA: A NOVEL APPROACH FOR DETECTION AND TREATMENT MONITORING  
T.L. Bothe<sup>(1)</sup>, G. Kuchler<sup>(2)</sup>, N. Pilz<sup>(3)</sup>, V. Heinz<sup>(4)</sup>, E. Hofmann<sup>(2)</sup>  
<sup>(1)</sup>Sydney (AUSTRALIA), <sup>(2)</sup>Randersacker, <sup>(3)</sup>Hannover, <sup>(4)</sup>Berlin (GERMANY)

09:09-09:15 *General Discussion*



## SATURDAY, MAY 30, 2026

09:30-10:30

GREEN ROOM

### Hypertensive Heart Disease or Something Else?

*Session organized by Club 30 of the Polish Cardiac Society*

Chairpersons: M. Jaguszewski (Gdańsk Poland), K. Ozieranski (Warsaw, POLAND), T. Weber (Wels, AUSTRIA)

09:30-09:40 Sarcomeric HCM vs. Hypertensive Heart Disease - Between Mimicry and Misdiagnosis

P. Sobieraj (Warsaw, POLAND)

09:40-09:50 Fabry Disease - The Ultra-Rare Chameleon in Hypertrophic Cardiomyopathy Clinics

A. Budaj-Fidecka (Warsaw, POLAND)

09:50-10:00 Cardiac Amyloidosis - When Hypertrophy Meets Hypotension

K. Holcman (Kraków, POLAND)

10:00-10:10 Beyond Wall Thickness: Emerging MRI Techniques to Endotype Left Ventricular Hypertrophy

J. Sokolska (Wrocław, POLAND)

10:10-10:20 Athlete's Heart - Sailing Between Physiology and Pathology

M. Spiewak (Warszawa, POLAND)

10:20-10:30 *General Discussion*

10:45-11:30

GREEN ROOM

### MINI-SYMPOSIUM SUPPORTED **BY GEDEON RICHTER**

Effective Treatment Strategies in Complex Clinical Scenarios: Stroke Prevention in Atrial Fibrillation with Hypertension and Diabetes

Chairperson: Z. Járαι (Budapest, HUNGARY)

10:45-10:50 Z. Járαι (Budapest, HUNGARY)

10:50-10:58 Rivaroxaban in complex clinical scenarios  
B. Benczúr (Szekszárd, HUNGARY)

10:58-11:06 Apixaban in complex clinical scenarios  
R.M. Bruno (Paris, FRANCE)

11:06-11:30 *Expert Debate and Discussion*



## SATURDAY, MAY 30, 2026

14:45-15:30

GREEN ROOM

### MINI-SYMPOSIUM SUPPORTED BY **MEDTRONIC**

Breaking barriers: tackling uncontrolled and resistant hypertension. The Symplicity<sup>TM</sup> blood pressure procedure

Chairperson: D. Hering (Gdańsk, POLAND)

14:45-14:47 Introduction  
D. Hering (Gdańsk, POLAND)

14:47-14:55 Who is the right patient? Evidence-based selection for Renal denervation  
K. Tsioufis (Athens, GREECE)

14:55-15:03 Does Renal Denervation lower cardiovascular risk? What the evidence shows  
R.E. Schmieder (Erlangen, GERMANY)

15:03-15:11 Where does Renal Denervation fit in Hypertension practice?  
A. Pathak (Luxembourg, LUXEMBOURG)

15:11-15:19 How do we connect the Dots? Building referral pathway for Renal Denervation  
T. Butt (Essex, UNITED KINGDOM)

15:19-15:29 *Interactive discussion: cases and lessons learned*

15:29-15:30 Conclusion  
D. Hering (Gdańsk, POLAND)

16:15-17:30

GREEN ROOM

### ORAL SESSION

Vascular Dysfunction and Remodeling

Chairpersons: A.M. Heagerty (Manchester, UNITED KINGDOM),  
F. Piani (Graz, AUSTRIA)

16:15-16:24 ELASTASE-2 (ELA-2/CELA-2A) AMPLIFIES ANGIOTENSIN II-DRIVEN INFLAMMATION AND MATRIX DEGRADATION IN HUMAN AND EXPERIMENTAL ABDOMINAL AORTIC ANEURYSM  
C. Becari<sup>(1)</sup>, F. Mestriner<sup>(1)</sup>, V. Flora Dugaich<sup>(2)</sup>, P. Bruch Dantas<sup>(2)</sup>, H. Kovacs<sup>(2)</sup>, J. Michelon-Barbosa<sup>(2)</sup>, C. Corsi<sup>(2)</sup>, M.C. Jordani<sup>(2)</sup>, P. Vargas Pinilla<sup>(2)</sup>, W. Piedade<sup>(1)</sup>, K. Polonis<sup>(3)</sup>, E. Joviliano<sup>(2)</sup>, M. Ribeiro<sup>(2)</sup>  
<sup>(1)</sup>Bauru, <sup>(2)</sup>Ribeirão Preto (BRAZIL), <sup>(3)</sup>MA (USA)

16:24-16:33 SKIN MICROVASCULAR FUNCTION PREDICTS 10-YEAR CARDIOVASCULAR RISK IN TREATMENT-NAÏVE HYPERTENSIVE AND NORMOTENSIVE INDIVIDUALS  
A. Malliora A. Lazaridis, K. Mastrogiannis, A. Chionidou, N. Tziolas, V. Kordalis, T. Athanasiadou, E. Gkaliagkousi  
Thessaloniki (GREECE)

16:33-16:42 ASSOCIATION BETWEEN TRIGLYCERIDES-GLUCOSE INDEX AND CAROTID PLAQUE. URIC ACID RIGHT FOR HEART HEALTH PROJECT  
M.L. Muiesan<sup>(1)</sup>, F. Cherubini<sup>(1)</sup>, C. Agabiti Rosei<sup>(1)</sup>, A. Maloberti<sup>(2)</sup>, C. Giannattasio<sup>(2)</sup>, E. Casiglia<sup>(3)</sup>, G. Desideri<sup>(4)</sup>, C. M. Barbagallo<sup>(5)</sup>, M. Cirillo<sup>(6)</sup>, P. Cirillo<sup>(7)</sup>, C. Ferri<sup>(8)</sup>, F. Galletti<sup>(9)</sup>, G. Grassi<sup>(10)</sup>, G. Iaccarino<sup>(9)</sup>, P. Palatini<sup>(3)</sup>, G. Parati<sup>(2)</sup>, R. Pontremoli<sup>(11)</sup>, M. Rattazzi<sup>(12)</sup>, M. Salvetti<sup>(1)</sup>, V. Tikhonoff<sup>(3)</sup>, P. Verdecchia<sup>(13)</sup>, M. Volpe<sup>(5)</sup>, A. Virdis<sup>(14)</sup>, C. Borghi<sup>(15)</sup>  
<sup>(1)</sup>Brescia, <sup>(2)</sup>Milan, <sup>(3)</sup>Padua, <sup>(4)</sup>Rome, <sup>(5)</sup>Palermo, <sup>(6)</sup>Baronissi/SA, <sup>(7)</sup>Bari, <sup>(8)</sup>L'Aquila, <sup>(9)</sup>Naples, <sup>(10)</sup>Monza, <sup>(11)</sup>Genoa, <sup>(12)</sup>Treviso, <sup>(13)</sup>Perugia, <sup>(14)</sup>Pisa, <sup>(15)</sup>Bologna (ITALY)



## SATURDAY, MAY 30, 2026

16:42-16:51 HOSPITALISATION WITH COVID 19 IS ASSOCIATED WITH WORSE VASCULAR REMODELLING IN MEN: THE CARTESIAN STUDY  
 S. Badhwar<sup>(1)</sup>, D.O. Sam<sup>(1)</sup>, M.R. Martina<sup>(2)</sup>, M. Agharazii<sup>(3)</sup>, J. Badariene<sup>(4)</sup>, J. Bellien<sup>(5)</sup>, L.A. Bortolotto<sup>(6)</sup>, A. Cantürk<sup>(7)</sup>, C. Fortier<sup>(3)</sup>, L. Ghiadoni<sup>(2)</sup>, A. Grillo<sup>(8)</sup>, B. Hametner<sup>(9)</sup>, C.B. Hondros<sup>(10)</sup>, A.D. Hughes<sup>(11)</sup>, I. Ikonomidis<sup>(12)</sup>, A. Laucyte-Cibulskiene<sup>(13)</sup>, M.T. Lønnebakken<sup>(10)</sup>, C.C. Mayer<sup>(9)</sup>, M.L. Muiesan<sup>(14)</sup>, M. Puato<sup>(8)</sup>, C. Rajkumar<sup>(15)</sup>, C.G. Ramos-Becerra<sup>(16)</sup>, B. Spronck<sup>(17)</sup>, L. Stoner<sup>(18,19)</sup>, D. Terentes-Printzios<sup>(12)</sup>, Y. Tunçok<sup>(20)</sup>, T. Weber<sup>(21)</sup>, P. Wohlfahrt<sup>(22)</sup>, L. Zanolli<sup>(23)</sup>, G. Zieff<sup>(24)</sup>, P. Boutouyrie<sup>(1)</sup>, R.M. Bruno<sup>(1)</sup>, E. Bianchini<sup>(2)</sup>  
<sup>(1)</sup>Paris (FRANCE), <sup>(2)</sup>Pisa (ITALY), <sup>(3)</sup>Québec City, Québec (CANADA), <sup>(4)</sup>Vilnius (LITHUANIA), <sup>(5)</sup>Rouen (FRANCE), <sup>(6)</sup>São Paulo (BRAZIL), <sup>(7)</sup>Istanbul (TURKEY), <sup>(8)</sup>Trieste (ITALY), <sup>(9)</sup>Vienna (AUSTRIA), <sup>(10)</sup>Bergen (NORWAY), <sup>(11)</sup>London (UNITED KINGDOM), <sup>(12)</sup>Athens (GREECE), <sup>(13)</sup>Malmö (SWEDEN), <sup>(14)</sup>Brescia (ITALY), <sup>(15)</sup>Brighton (UNITED KINGDOM), <sup>(16)</sup>Guadalajara (MEXICO), <sup>(17)</sup>Maastricht (THE NETHERLANDS), <sup>(18)</sup>Auckland (NEW ZEALAND), <sup>(19)</sup>Scienceye (NC, USA), <sup>(20)</sup>Izmir (TURKEY), <sup>(21)</sup>Wels (AUSTRIA), <sup>(22)</sup>Prague (CZECH REP.), <sup>(23)</sup>Catania (ITALY), <sup>(24)</sup>Vancouver (CANADA)

16:51-17:00 HEART-VESSEL CROSSTALK: ASSOCIATION BETWEEN LEFT VENTRICULAR DIASTOLIC FUNCTION AND MACROVASCULAR REACTIVITY, CAPTURED BY BRACHIAL-RADIAL FLOW-MEDIATED SLOWING  
 M. Renier<sup>(1)</sup>, T. Kuznetsova<sup>(1)</sup>, Y. Bekhuis (1,2), J. Claes<sup>(1)</sup>, E. Santana<sup>(1)</sup>, G. Claessen (1,2,3), A. Van Craenenbroeck<sup>(1)</sup>, E. Van Craenenbroeck<sup>(4)</sup>, K. Goetschalckx<sup>(1)</sup>, D. Hansen<sup>(2)</sup>, D. De Smedt<sup>(5)</sup>, V. Cornelissen<sup>(1)</sup>, N. Cauwenberghs<sup>(1)</sup>  
<sup>(1)</sup>Leuven, <sup>(2)</sup>Diepenbeek, <sup>(3)</sup>Hasselt, <sup>(4)</sup>Antwerp, <sup>(5)</sup>Ghent (BELGIUM)

17:00-17:15 **LECTURE**  
**The Vasculome in Hypertension: Oxidative Stress to Precision Medicine**  
 R. Touyz (Montreal, CANADA)

17:15-17:30 *General Discussion*

08:30-10:00

ORANGE ROOM

### HANDS-ON WORKSHOPS

#### Large Arteries in Hypertension (Fundamentals and Practice)

Chairpersons: E. Bianchini (Pisa, ITALY), D. Terentes Printzios (Athens, GREECE)

08:30-08:40 Assessment of Arterial Stiffness: History and Background  
 S. Laurent (Paris, FRANCE)

08:40-08:50 Proper Assessment of Arterial Stiffness in the Hypertensive Patient  
 G. Pucci (Terni, ITALY)

08:50-09:00 Recommendations Applied in the Clinical Practice  
 A. Protogerou (Athens, GREECE)

09:00-10:00 Practical Examples of Clinical Scenarios  
 A. Argyris (Athens, GREECE)



## SATURDAY, MAY 30, 2026

14:45-15:45

ORANGE ROOM

### HANDS-ON WORKSHOPS

#### Echocardiography in Hypertension (Fundamentals and Practice)

Chairpersons: M. Camafort (Barcelona, SPAIN), A. Kasiakogias (Athens, GREECE)

- 14:45-14:55 The Basic Echocardiographic Study and when to integrate it in the evaluation of the Hypertensive Patient  
L. Anghel (Iasi, ROMANIA)
- 14:55-15:05 Left Ventricular Hypertrophy in Hypertension. A step-by-step guide to Echocardiographic Evaluation  
L. Faconti (London, UNITED KINGDOM)
- 15:05-15:15 Echocardiographic Assessment of Diastolic Function in Hypertension. From Guidelines to Clinical Practice  
N.R. Pugliese (Pisa, ITALY)
- Practical session:*
- 15:15-15:45 Demonstration of echocardiographic techniques by experts. Supervised hands-on echocardiography with healthy volunteers or simulators  
L. Anghel (Iasi, ROMANIA)

16:15-17:15

ORANGE ROOM

### HANDS-ON WORKSHOPS

#### Sympathetic Nervous System (SNS) and Hypertension

Chairpersons: G. Grassi (Milan, ITALY), M. Schlaich (Perth, AUSTRALIA)

- 16:15-16:20 When and why should we assess SNS activity in Hypertension  
P. Van de Borne (Brussels, BELGIUM)
- 16:20-16:35 How to assess SNS: Non-Invasive Approaches  
G. Parati (Milan, ITALY)
- 16:35-16:50 How to assess SNS: Invasive Approaches  
D. Hering (Gdańsk, POLAND)
- 16:50-17:05 Innovative Approaches  
G. Wuerzner (Lausanne, SWITZERLAND)
- 17:05-17:15 Integration in daily practice and future directions  
A. Pathak (Luxembourg, LUXEMBOURG)



## SATURDAY, MAY 30, 2026

09:15-09:35

MEET-THE-EXPERT HUB

*Meet-the-Expert supported by **AstraZeneca***

ReThinking the role of Aldosterone in hypertension, cardiovascular-kidney and metabolic risk

Expert: M. Schlaich (Perth, AUSTRALIA)

11:30-11:50

MEET-THE-EXPERT HUB

*Meet-the-Expert supported by **MENARINI GROUP***

From cardiovascular risk to cardiovascular prevention in comorbid hypertension: navigating the cardiovascular continuum

Expert: A. Januszewicz (Warsaw, POLAND)

12:50-13:10

MEET-THE-EXPERT HUB

*Meet-the-Expert supported by **SERVIER***

From wearables to AI in Hypertension

12:50-13:05 From Wearables to AI in Hypertension: What Works, What Doesn't, and What's Next?

Expert: A. Petre (Paris, FRANCE)

13:05-13:10 Q&A

14:30-14:50

MEET-THE-EXPERT HUB

*Meet-the-Expert supported by **MENARINI GROUP***

Lipoprotein(a): a big piece of the CVD risk factor puzzle

Expert: K.G. Parhofer (Munich, GERMANY)

16:00-16:20

MEET-THE-EXPERT HUB

*Meet-the-Expert supported by **SERVIER***

Maximizing Cardiovascular care in Hypertensive patients

Panelists: A.M. Vintila (Bucharest, ROMANIA), M. Strauss (Toronto, CANADA)

16:00-16:08 Reframing the Evidence: New Insights from Meta-Analyses  
M. Strauss (Toronto, CANADA)

16:08-16:16 Single-Pill Combinations in Hypertension Elevating treatment Impact  
A.M. Vintila (Bucharest, ROMANIA)

16:16-16:20 Q&A



## SATURDAY, MAY 30, 2026

10:15- 10:45

PATIENT JOURNEY / LEARNING ROOM

**Expert Insight Session**

*This activity is provided by Nexus Healthcare Education and supported by an independent educational grant from AstraZeneca*

Deep-dive into latest clinical trial design for ASIs  
B. Williams (London, UNITED KINGDOM)

15:30 – 16:00

PATIENT JOURNEY / LEARNING ROOM

**Expert Insight Session**


*This activity is provided by Nexus Healthcare Education and supported by an independent educational grant from AstraZeneca*

ASIs - Implications for future hypertension guidelines  
K. Narkiewicz (Gdańsk, POLAND)

17.45-19.00

E-POSTER SESSIONS

Totem 1	Adherence
Totem 2	BP Measurement and Monitoring III
Totem 3	Cardiometabolic Hypertension
Totem 4	Clinical Studies II
Totem 5	Device Based Treatment
Totem 6	Epidemiology II
Totem 7	Epidemiology III
Totem 8	Heart II
Totem 9	Hypertension Phenotypes II
Totem 10	Kidney
Totem 11	Obesity
Totem 12	Pathophysiology and Mechanisms II
Totem 13	Pharmacotherapy II
Totem 14	Real-World Evidence Research II
Totem 15	Resistant Hypertension
Totem 16	Risk Factors II
Totem 17	Vascular Biology II
Totem 18	Women



## Patient Journey Learning Room

# Redefining the Patient Journey in Persistent Uncontrolled Hypertension

Friday 29 May, 09:00–17:00 CEST  
Saturday 30 May, 09:00–17:00 CEST



### Step Inside a New Way of Learning

An immersive, self-guided experience mapping the biological drivers of hypertension across the patient journey. Drop in anytime and learn at your own pace. *Coffee and refreshments provided.*




#### IMMERSIVE DIGITAL WALL

Experience a large-scale animated digital wall that brings to life the scientific foundations underlying hypertension.




#### AI-PERSONALISED LEARNING

Explore the content in greater depth by engaging with our customised AI agent, designed to answer your questions and expand your understanding.  
*Accredited for 0.5 CME credits.*



#### EXPERT INSIGHT SESSIONS

Gain practical clinical perspectives from leading experts, Reinhold Kreutz, Alta Schutte, Bryan Williams, and Krzysztof Narkiewicz.



#### DOWNLOADABLE RESOURCES

Take away key visuals and a curated slide set to support knowledge sharing with colleagues and reinforce continued learning.



## Expert Insight Sessions Schedule

FRI  
29 | 05



**Reinhold Kreutz**

09:30-10:00

Practical strategies to facilitate adoption of ASIs



**Alta Schutte**

15:30-16:00

From clinical trials to the clinic – How will ASIs be used in real-world practice?

SAT  
30 | 05



**Bryan Williams**

10:15-10:45

Deep-dive into latest clinical trial design for ASIs



**Krzysztof Narkiewicz**

15:30-16:00

ASIs – Implications for future hypertension guidelines



### Accreditation

The accredited part of this activity (AI-driven personalised learning) is jointly provided by Partners for Advancing Clinical Education and Nexus Healthcare Education. Partners designates this activity for a maximum of 0.5 *AMA PRA Category 1 Credit™*.



For more information  
click here.



**ESH** Gdańsk  
2026

**SUNDAY, 28 MAY**





## SUNDAY, MAY 31, 2026

08:30-09:45

BLUE ROOM

### ORAL SESSION

#### Hypertension in Women

Chairpersons: M. Dorobantu (Bucharest, ROMANIA), A. Szyndler (Gdańsk, POLAND)

08:30-08:45 **LECTURE**

#### Why it is difficult to treat Hypertension in Pregnancy

R. Cifková (Prague, CZECH REPUBLIC)

08:45-08:54 EARLY IMMUNE ALTERATIONS IN PLACENTA-RELATED COMPLICATIONS ARE ASSOCIATED WITH LONGITUDINAL MATERNAL IMMUNOGLOBULIN GLYCOSYLATION PROFILES IN PREGNANCY

L. Voskamp<sup>(1)</sup>, M. Rousian<sup>(1)</sup>, A. Daniels<sup>(1)</sup>, M. Wuhler<sup>(2)</sup>, A.H.J. Danser<sup>(1)</sup>, R.P.M. Steegers-Theunissen<sup>(2)</sup>, K. Verdonk<sup>(1)</sup>  
<sup>(1)</sup>Rotterdam, <sup>(2)</sup>Leiden (THE NETHERLANDS)

08:54-09:03 SECOND TRIMESTER AMBULATORY BLOOD PRESSURE MONITORING IS THE MOST PREDICTIVE TIMING FOR A COMPOSITE ADVERSE PREGNANCY OUTCOME

M. Santos Silva, T. Aguiar, I. Cruz, C. Costa, S. Carvalho, A. Faustino, J. Mesquita Bastos  
Aveiro (PORTUGAL)

09:03-09:12 THE sFIT-1/PIGF RATIO IN A SUBSEQUENT PREGNANCY AFTER PREECLAMPSIA

A. Kluivers, B. Pandango, R. Neuman, W. Visser, A.H.J. Danser, L. Saleh  
Rotterdam (THE NETHERLANDS)

09:12-09:21 POSTPARTUM BLOOD PRESSURE PHENOTYPES ONE YEAR AFTER PREECLAMPSIA

S. Sabnani, M. van der Bijl, J. Versmissen, E. Boersma, J. Duvekot, L. Saleh, A.H.J. Danser, K. Verdonk, J. Roeters van Lennep  
Rotterdam (THE NETHERLANDS)

09:21-09:30 POSTMENOPAUSAL STATUS IDENTIFIES A HIGH-RISK ABPM PROFILE IN HYPERTENSIVE WOMEN: DAYTIME BP ELEVATION, RISER PATTERN, AND ORGAN DAMAGE

W. Wang, L. Zhu, M. Qi, R. Sun, X. Fan, J. Yu  
Lanzhou (CHINA)

09:30-09:39 SEX DIFFERENCES IN CARDIOVASCULAR RISK AFTER EMERGENCY DEPARTMENT DISCHARGE FOR HYPERTENSIVE URGENCIES

G. Prado Paz, R. Gómez Villaplana, C. Gargallo Maicas, P. Urueña Lopez, L. Gil Senabre, P. Romero Crespo, G. Huerta Rubio, A. Mercado Pardo, E. Peinado Castello, I. Sauri, E. Solaz Moreno, D. Ruiz Raga, C. Prades, A. Lucas Camps, A. Marco Gabarre, J. Redon Mas, F. Martinez García  
Valencia (SPAIN)

09:39-09:45 *General Discussion*



## SUNDAY, MAY 31, 2026

10:00-11:00

BLUE ROOM

**From early coronary events to lifelong risk: rethinking cardiovascular disease in young women**

*Joint Session with ESC (European Society of Cardiology)*

Chairpersons: T. Guzik (Kraków, POLAND/Edinburgh, UNITED KINGDOM),  
 T. Weber (Wels, AUSTRIA)

10:00-10:02 Introduction  
 T. Guzik (Kraków, POLAND/Edinburgh, UNITED KINGDOM)

10:02-10:14 Acute coronary syndrome phenotypes in young women  
 D. Adlam (Leicester, UNITED KINGDOM)

10:14-10:26 Vascular diseases in young women  
 I. Sudano (Zurich, SWITZERLAND)

10:26-10:38 Long-term cardiovascular risk after pregnancy complications  
 J. Brguljan Hitij (Ljubljana, SLOVENIA)

10:38-10:58 *Panel Discussion*

10:58-11:00 Summary  
 T. Weber (Wels, AUSTRIA)

11:15-12:15

BLUE ROOM

**Hypertension in Space**

Chairpersons: S. Carlier (Mons, BELGIUM), G. Parati (Milan, ITALY)

11:15-11:30 From Space to Bedside  
 V. Heinz (Berlin, GERMANY)

11:30-11:45 Hyper(tension)-Space: Blood Pressure in Astronauts  
 T.L. Bothe (Hobart, AUSTRALIA)

11:45-11:55 Human Spaceflight as Clinical Research Platform  
 S. Carlier (Mons, BELGIUM)

11:55-12:15 *General Discussion*

12:30-13:45

BLUE ROOM

**The Best of the ESH 2026 Congress: From Discovery to Future Practice**

Chairpersons: D. Ferrão (Porto, PORTUGAL),  
 Z. Járαι (Budapest, HUNGARY),  
 A. Januszewicz (Warsaw, POLAND)

12:30-12:40 **Presentation of the Awards for the Best Original Presentations**

12:40-12:50 From Bench to Bedside: Translational Advances in Cardiovascular Disease  
 A.H.J. Danser (Rotterdam, THE NETHERLANDS)

12:50-13:00 Device Innovations: The Next Generation of Cardiovascular Technologies  
 R. M. Bruno (Paris, FRANCE)

13:00-13:10 Other Innovations in Cardiometabolic Care  
 C. Delles (Glasgow, UNITED KINGDOM)

13:10-13:20 New Clinical Trials: Where Are We Heading Next?  
 M. Azizi (Paris, FRANCE)

13:20-13:30 Interventional Treatment of Hypertension: From Renal Denervation to the Next Wave  
 K. Tsioufis (Athens, GREECE)

13:30-13:40 Clinical Practice Update: What Should We Do Differently Now?  
 R. de Pinho (São João da Madeira, PORTUGAL)

13:40-13:45 Looking Ahead to ESH 2027 in Basel  
 M. Burnier (Lausanne, SWITZERLAND)  
 B. Ponte (Geneva, SWITZERLAND)  
 N. Peters (Zürich, SWITZERLAND)



## SUNDAY, MAY 31, 2026

08:30-09:45

RED ROOM

### CLINICAL CASES - SESSION 3

Clinical-Pathological Conference (CPC) in cooperation with Hypertension, an American Heart Association Journal (AHA)

Chairpersons: J. Cluett (Boston, MA, USA),  
 S. Daskalopoulou (Montreal, CANADA),  
 R. Touyz (Montreal, CANADA)

08:30-09:05 Severe, complicated presentation of Fibromuscular Dysplasia in a 68-Year-Old Patient  
 J. Pirotte (Brussels, BELGIUM), A. Persu (Brussels, BELGIUM)

09:05-09:40 Primary Aldosteronism Masquerading as Secondary Hyperaldosteronism  
 Y.-B. Cheng (Shanghai, CHINA), Q.-H. Guo (Shanghai, CHINA),  
 J.-G. Wang (Shanghai, CHINA)

09:40-09:45 *General Discussion*

10:00-11:00

RED ROOM

### Pro-Con Session on Basic Assessment of Patients with Hypertension

Chairpersons: S. Erdine (Istanbul, TURKEY), J. Redon (Valencia, SPAIN)

#### **Debate 1: Risk prediction for all?**

10:00-10:15 Pro  
 L. Bronze (Lisbon, PORTUGAL)

10:15-10:30 Con  
 F. Messerli (Bern, SWITZERLAND)

#### **Debate 2: Renin Aldosterone Ratio Analysis for all?**

10:30-10:45 Pro  
 P. Mulatero (Turin, ITALY)

10:45-11:00 Con  
 B. Williams (London, UNITED KINGDOM)

11:15-12:15

RED ROOM

### Navigating Practical Management Issues in Hypertension and CKD

*Joint Session with ERA (European Renal Association)*

Chairpersons: M. Adamczak (Katowice, POLAND),  
 M. Pruijm (Lausanne, SWITZERLAND)

11:15-11:17 Introduction  
 A. Wiecek (Katowice, POLAND)

11:17-11:29 When and how to use 24-h Ambulatory Blood Pressure Monitoring in Patients with CKD  
 L.V. Halvorsen (Oslo, NORWAY)

11:29-11:41 Use of RAS Inhibitors in Patients with CKD stage 4 and 5: What to do and What not to do  
 M. Adamczak (Katowice, POLAND)

11:41-11:53 Differential Use of Diuretics in Hypertensive Patients with CKD  
 A. Wiecek (Katowice, POLAND)

11:53-12:13 *Panel Discussion*

12:13-12:15 Summary  
 M. Pruijm (Lausanne, SWITZERLAND)



## SUNDAY, MAY 31, 2026

08:30-09:45

YELLOW ROOM

### ORAL SESSION

#### Kidney in Hypertension

Chairpersons: M. Miglinas (Vilnius, LITHUANIA), B. Ponte (Geneva, SWITZERLAND)

08:30-08:39 PREVALENCE AND NATURE OF ARTERIAL LESIONS IDENTIFIED BY WHOLE-BODY CT ANGIOGRAPHY IN FIBROMUSCULAR DYSPLASIA, SPONTANEOUS CORONARY ARTERY DISSECTION OR DISSECTING/ ANEURYSMAL DISEASE  
T. Robberechts<sup>(1)</sup>, A. Paterson<sup>(1)</sup>, P. Delmotte<sup>(1,2)</sup>, M.S. Stoenoiu<sup>(1)</sup>, A. Persu<sup>(1)</sup>  
<sup>(1)</sup> Brussels, <sup>(2)</sup> Mons (BELGIUM)

08:39-08:48 FOLLOW-UP OF RENAL FUNCTION IN PATIENTS WITH FIBROMUSCULAR DYSPLASIA  
P.W. de Leeuw, P. Zelis, M.T. Schutten, A.A Kroon  
Maastricht (THE NETHERLANDS)

08:48-08:57 PERFORMANCE OF GLOMERULAR FILTRATION RATE ESTIMATION FORMULAE IN PRIMARY ALDOSTERONISM  
D. Bagordo<sup>(1)</sup>, A. Marangon<sup>(2)</sup>, G. Pintus<sup>(3)</sup>, B. Caroccia<sup>(2)</sup>, G. Bertoldi<sup>(4)</sup>, M.T. Seccia<sup>(2)</sup>, G.P. Rossi<sup>(2)</sup>, G. Rossitto<sup>(2,5)</sup>  
<sup>(1)</sup> Pavia, <sup>(2)</sup> Padua, <sup>(3)</sup> Rome (ITALY), <sup>(4)</sup> Charlottesville, VA (USA), <sup>(5)</sup> Glasgow (UNITED KINGDOM)

08:57-09:12 **LECTURE**  
**Beyond Hypertension Control to cure Kidney Disease in African Ancestry Patients: APOL1**  
B.I. Freedman (Winston-Salem, NC, USA)

09:12-09:21 GLUTREPRO: A RANDOMIZED CONTROLLED TRIAL OF SGLT2 INHIBITORS ON RENAL SENESENCE, INFLAMMATION, AND TUBULOINTERSTITIAL INJURY IN CHRONIC KIDNEY DISEASE  
E. Russo, D. Verzola, F. Cappadona, N. Rumeo, L. Macciò, P. Esposito, G. Garibotto, F. Viazzi  
Genoa (ITALY)

09:21-09:30 CARDIOVASCULAR RISK IN HEMODIALYSIS PATIENTS BEYOND TRADITIONAL RISK FACTORS: LONG-TERM IMPACT OF PULSE-WAVE VELOCITY AND CARDIAC BIOMARKERS  
A. Stefan, A. Covic, M.A. Covic, G. Dodi, M. Apetrei, M. Onofriescu, S. Hogas, S. Iliescu, L. Voroneanu  
Iasi (ROMANIA)

09:30-09:39 RELATIONSHIP BETWEEN DIURNAL URINE SODIUM EXCRETION AND NOCTURNAL BLOOD PRESSURE IN KIDNEY TRANSPLANT RECIPIENTS  
A. Georgiou, F. Iatridi, M.P. Theodorakopoulou, A.G. Theodosiadi, E. Karkamani, A.G. Karagiannidis, E. Sampani, C.A. Dimitriadis, G. Miserlis, P. Sarafidis  
Thessaloniki (GREECE)

09:39-09:45 *General Discussion*



## SUNDAY, MAY 31, 2026

10:00-10:45

YELLOW ROOM

### MINI-SYMPOSIUM SUPPORTED BY POLISH LIPID ASSOCIATION / INTERNATIONAL LIPID EXPERT PANEL

Beyond Blood Pressure: A Multirisk, Multimorbidity Strategy for  
Cardiovascular Prevention - Visions for 2026 and Beyond

Chairpersons: A. Covic (Iasi, ROMANIA), R. Gil (Warsaw, POLAND)

10:00-10:12 2026 Lipid-Management Guidelines for High-Risk Patients:  
Cutting-Edge Strategies to Halt Atherosclerosis Progression  
M. Banach (Lublin, POLAND)

10:12-10:24 Personalised Prevention for Patients with Dyslipidaemia,  
Hypertension, and Elevated hs-CRP: The Key to Optimal  
Cardiovascular Care  
M. Viigimaa (Tallinn, ESTONIA)

10:24-10:36 Very-High and Extreme-Risk Patients with Multimorbidity:  
Navigating Intensive Polytherapy, Drug Interactions, and Adherence  
A. Postadzhiyan (Sofia, BULGARIA)

10:36-10:45 *Panel Discussion*

08:30-09:45

PURPLE ROOM

### ORAL SESSION

#### Resistant Hypertension

Chairpersons: T. Angoulvant (Tours, FRANCE), D. Lovic (Niš, SERBIA)

08:30-08:39 AGE DIFFERENCES IN END-ORGAN DAMAGE AND RISK OF  
CARDIOVASCULAR EVENTS AND MORTALITY IN APPARENT  
TREATMENT RESISTANT HYPERTENSION  
L. Bortolotto, M. Solimene, R. Garcia, R. Miada  
Sao Paulo (BRAZIL)

08:39-08:48 RARE VARIANT ANALYSIS OF APPARENT TREATMENT  
RESISTANT HYPERTENSION WITHIN THE UK BIOBANK  
S. Mitchell, R. Murphy, D. Lees-Murdock, M. Ward  
Coleraine (UNITED KINGDOM)

08:48-08:57 BEYOND RESISTANCE: DETERMINANTS OF MULTIPLE  
ANTIHYPERTENSIVE DRUG INTOLERANCE AND DEVELOPMENT  
OF A CLINICAL RISK SCORE

M. Regolo, L. Ponsa, M. Genovese, M. Lanza, I. Vesely,  
C. Bertello, S. Monticone, F. Veglio, P. Mulatero, F. Rabbia,  
M. Pappaccogli  
Turin (ITALY)

08:57-09:06 BLOOD PRESSURE LOWERING EFFECTS OF PHARMACOLOGICAL  
AND DEVICE-BASED INTERVENTIONS FOR RESISTANT  
HYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSIS  
K. Kyriakoulis<sup>(1)</sup>, A. Vakka<sup>(1)</sup>, N. Stamataki<sup>(1)</sup>, F. Tatakis<sup>(1)</sup>,  
D. Konstantinidis<sup>(1)</sup>, C. Mihas<sup>(1)</sup>, S. Soulaïdopoulos<sup>(1)</sup>, A. Kasiakogias<sup>(1)</sup>,  
A. Kordalis<sup>(1)</sup>, C. Thomopoulos<sup>(1)</sup>, M. Doumas<sup>(2)</sup>, G.S. Stergiou<sup>(1)</sup>,  
M. Schlaich<sup>(3)</sup>, M. Böhm<sup>(4)</sup>, K. Tsioufis<sup>(1)</sup>  
<sup>(1)</sup> Athens, <sup>(2)</sup> Thessaloniki (GREECE), <sup>(3)</sup> Perth (AUSTRALIA),  
<sup>(4)</sup> Homburg (GERMANY)

09:06-09:15 RENAL DENERVATION IN UNCONTROLLED HYPERTENSIVE  
PATIENTS WITH RENAL ARTERY STENOSIS ASSESSED BY INVASIVE  
PHYSIOLOGY  
A. Sarai, D. Tavella, G. Pesarini, A. Gambaro, F. Vigo, E. Galuppi,  
M. Casal, A. Trevisanello, L. Trento, M. Piscopo, G. Previdi, V. Galli,  
C. Gangemi, V. Ferrero, R. Scarsini, S. Fezzi, G. Gambaro, M. Ferraro,  
F.L. Ribichini  
Verona (ITALY)

09:15-09:30 **LECTURE:**  
**Practical Management of Malignant Hypertension**  
R. Boulestreau (Bordeaux, FRANCE)

09:30-09:39 PROTEOMIC PREDICTORS OF BLOOD PRESSURE RESPONSE  
POST RENAL DENERVATION IN HYPERTENSIVE PATIENTS  
D. Polyzos, S. Drogkaris, M. Makridakis, F. Tatakis,  
D. Konstantinidis, C. Fragoulis, A. Vakka, A. Vlahou, K. Tsioufis  
Athens (GREECE)

09:39-09:45 *General Discussion*



## SUNDAY, MAY 31, 2026

10:00-10:45

PURPLE ROOM

### MINI-SYMPOSIUM SUPPORTED **BY BAUSCH HEALTH**

#### Therapeutic Inertia: The Enemy of Success

Chairpersons: M. Burnier (Lausanne, SWITZERLAND),  
K. Narkiewicz (Gdańsk, POLAND)

10:00-10:05 Introduction  
M. Burnier (Lausanne, SWITZERLAND)

#### *Therapeutic inertia and hypertension in Europe:*

10:05-10:15 The Dutch experience  
B.-J. van den Born (Amsterdam, THE NETHERLANDS)

10:15-10:25 The Polish experience  
K. Narkiewicz (Gdańsk, POLAND)

10:25-10:45 *Round table discussion with the audience: How can we mitigate the impact of therapeutic inertia?*

08:30-09:45

GREEN ROOM

### ORAL SESSION

#### Molecular Mechanisms

Chairpersons: G. Lembo (Rome/Pozzilli, ITALY), T. Smolenski (Gdańsk, POLAND)

08:30-08:39 VEGFR3 MITIGATES HYPERTENSIVE NEPHROPATHY BY ENHANCING MITOPHAGY VIA REGULATING CROTONYLATION OF HSPA1L  
Q. Wu, S. Zhang  
Harbin (CHINA)

08:39-08:48 LOW-GRADE TYPE I INTERFERON ACTIVATION PROTECTS AGAINST HYPERTENSION TARGET-ORGAN DAMAGE IN A SUSCEPTIBLE MURINE MODEL  
A. Orieux, R. Boulestreau, M.-L. Bats, A. Boyer, C. Peghaire, C. Duplaa, T. Couffinhall, S. Rubin  
Pessac (FRANCE)

08:48-08:57 HIGHER EXPRESSION OF MIRNA-155 AND MIRNA-103 IN PATIENTS WITH GITELMAN SYNDROME: POTENTIAL IMPLICATIONS FOR ANGIOTENSIN II-INDUCED CARDIOVASCULAR REMODELING IN HYPERTENSION  
M. Cacciapuoti<sup>(1)</sup>, I. Caputo<sup>(1)</sup>, G. Driussi<sup>(1)</sup>, F. Nalesso<sup>(1)</sup>, P.A. Davis<sup>(2)</sup>, L.A. Calò<sup>(1)</sup>  
<sup>(1)</sup>Padua (ITALY), <sup>(2)</sup>Davis, CA (USA)

08:57-09:06 SMALL RNA PROFILING OF CIRCULATING EXTRACELLULAR VESICLES FROM PATIENTS WITH ADRENAL-PRODUCING ADENOMAS  
F. Buffolo, J. Burrello, S. Tarallo, A. Naccarati, G. Leone, G. Birolo, F. Veglio, P. Mulatero, B. Pardini, S. Monticone  
Turin (ITALY)



## SUNDAY, MAY 31, 2026

09:06-09:15 A HUMAN 3D CARDIAC MICROTISSUE MODEL TO INVESTIGATE ALDOSTERONE-INDUCED FIBROSIS AND ELECTRICAL DYSFUNCTION

J. Burrello<sup>(1)</sup>, G. Senesi<sup>(2)</sup>, C. Altomare<sup>(2)</sup>, F. Buffolo<sup>(1)</sup>,  
F. D'Ascenzo<sup>(1)</sup>, L. Barile<sup>(2)</sup>, P. Mulatero<sup>(1)</sup>, C. Balbi<sup>(3)</sup>,  
S. Monticone<sup>(1)</sup>

<sup>(1)</sup> Turin (ITALY), <sup>(2)</sup> Bellinzona, <sup>(3)</sup> Schlieren (SWITZERLAND)

09:15-09:30 **LECTURE**  
**Stem Cell-Driven Renoprotection by Inhibiting Aldosterone Signaling**

M.S. Fernandez-Alfonso (Madrid, SPAIN)

09:30-09:45 *General Discussion*

10:00-10:45 GREEN ROOM

### MINI-SYMPOSIUM SUPPORTED **BY PRO.MED.**

Why and when hypertension experts and cardiologists should discuss patient's liver.

Case studies debate.

Experts in panel discussion

W. Bik (Warsaw, POLAND), M. Gierlotka (Opole, POLAND), A. Prejbisz (Warsaw, POLAND)

08:30-10:00

ORANGE ROOM

### HANDS-ON WORKSHOPS

**Ultrasound of Carotid Arteries - Practical USG Workshops (Hands-on). From Anatomical Basics to Clinical Practice**  
*Session organized by Club 30 of the Polish Cardiac Society*

#### Part I

08:30-08:50 Theoretical Introduction

1. Anatomy and ultrasound imaging of the carotid and vertebral arteries
  2. Ultrasound examination technique
  3. Intima-media complex and atherosclerotic plaque
  4. Assessment of the degree of stenosis
  5. Clinical indications for the examination
- E. Dziewiecka (Kraków, POLAND), P. Sobieraj (Warsaw, POLAND)

#### Part II

08:50-09:00 Examination Demonstration (Live Scanning)  
E. Dziewiecka (Kraków, POLAND), P. Sobieraj (Warsaw, POLAND)

#### Part III

09:00-10:00 Practical Workshops (Hands-on)  
E. Dziewiecka (Kraków, POLAND), P. Sobieraj (Warsaw, POLAND)



36<sup>TH</sup>  
JUNE 10-13  
2027

ESH

EUROPEAN MEETING ON HYPERTENSION  
AND CARDIOVASCULAR PROTECTION

Messe and  
Congress Center **BASEL**



SAVE THE DATE